@NP	Bone marrow	1
@NP	mesenchymal stromal cells and olfactory ensheathing cells	13
@NP	mesenchymal stromal cells	13
@NP	olfactory ensheathing cells	43
@NP	transplantation after spinal cord injury	71
@NP	transplantation	71
@NP	spinal cord injury	93
@NP	a morphological and functional comparison in rats	114
@NP	a morphological and functional comparison	114
@NP	rats	159
@NP	Abel Torres-Esp ın	165
@NP	Abel Torres-Esp	165
@NP	ın	181
@NP	,1,2 Elena Redondo-Castro ,1,2 Joaquim Hern andez1 ,2 and Xavier Navarro1	183
@NP	,1,2 Elena Redondo-Castro ,1,2 Joaquim Hern andez1 ,2	183
@NP	Xavier Navarro1	239
@NP	,2 1Department of Cell	254
@NP	,2 1Department	254
@NP	Cell	272
@NP	Biology , Physiology and Immunology , Group of Neuroplasticity and Regeneration	277
@NP	Biology , Physiology and Immunology , Group	277
@NP	Neuroplasticity and Regeneration	322
@NP	Institute of Neurosciences , Edif	356
@NP	Institute	356
@NP	Neurosciences , Edif	369
@NP	M	390
@NP	Universitat Aut onoma de Barcelona	393
@NP	Bellaterra E-08193	429
@NP	Spain 2Centro de Investigaci on Biom	449
@NP	Spain 2Centro de Investigaci	449
@NP	Biom	481
@NP	edica en Red sobre Enfermedades Neurodegenerativas -LRB- CIBERNED -RRB-	486
@NP	edica en Red sobre	486
@NP	Enfermedades Neurodegenerativas -LRB- CIBERNED -RRB-	505
@NP	Enfermedades Neurodegenerativas	505
@NP	CIBERNED	538
@NP	Spain Abstract Cell therapy for spinal cord injury	549
@NP	Spain Abstract Cell therapy	549
@NP	spinal cord injury	582
@NP	SCI	602
@NP	a promising strategy for clinical application	610
@NP	a promising strategy	610
@NP	clinical application	635
@NP	Both bone marrow mesenchymal stromal cells	657
@NP	MSCs ; also known as bone marrow-derived ` mesenchymal stem cells '	701
@NP	MSCs	701
@NP	bone marrow-derived ` mesenchymal stem cells '	721
@NP	bone marrow-derived	721
@NP	mesenchymal stem cells '	742
@NP	mesenchymal stem	742
@NP	cells '	759
@NP	olfactory ensheathing cells	771
@NP	OECs	800
@NP	beneficial effects following transplantation in animal models of SCI	824
@NP	beneficial effects	824
@NP	transplantation in animal models of SCI	853
@NP	transplantation	853
@NP	animal models of SCI	872
@NP	animal models	872
@NP	SCI	889
@NP	the large number	910
@NP	parameters	940
@NP	the therapy success and the lack of methodological consensus	966
@NP	the therapy success	966
@NP	the lack of methodological consensus	990
@NP	the lack	990
@NP	methodological consensus	1002
@NP	the comparison of different works	1028
@NP	the comparison	1028
@NP	different works	1046
@NP	we	1087
@NP	the effects of MSC and OEC transplants	1099
@NP	the effects	1099
@NP	MSC and OEC transplants	1114
@NP	early or delayed time	1141
@NP	a spinal cord contusion injury in the rat	1169
@NP	a spinal cord contusion injury	1169
@NP	the rat	1203
@NP	Functional outcomes	1212
@NP	locomotion , sensory perception and electrophysiological responses	1236
@NP	locomotion	1236
@NP	sensory perception	1248
@NP	electrophysiological responses	1271
@NP	the grafted cells survival and the amount of cavity and spared tissue	1327
@NP	the grafted cells survival	1327
@NP	the amount	1358
@NP	cavity and spared tissue	1372
@NP	cavity	1372
@NP	spared tissue	1383
@NP	The findings	1411
@NP	grafted cells	1438
@NP	7 days	1467
@NP	the following 2 weeks	1518
@NP	the low survival of the cells	1549
@NP	the low survival	1549
@NP	the cells	1569
@NP	MSC and OEC	1580
@NP	tissue protection	1608
@NP	early and delayed transplantation	1632
@NP	only acute MSC grafts	1681
@NP	locomotion recovery	1712
@NP	treadmill condition and electrophysiological outcomes	1735
@NP	treadmill condition	1735
@NP	electrophysiological outcomes	1759
@NP	respect	1794
@NP	the other injured groups	1805
@NP	These results , together with previous works ,	1831
@NP	These results	1831
@NP	previous works	1860
@NP	the MSC	1890
@NP	a better option	1903
@NP	OEC for treatment of contusion injuries	1924
@NP	OEC	1924
@NP	treatment of contusion injuries	1932
@NP	treatment	1932
@NP	contusion injuries	1945
@NP	Introduction Spinal cord injury -LRB- SCI -RRB-	1966
@NP	Introduction Spinal cord injury	1966
@NP	Introduction	1966
@NP	Spinal cord injury	1979
@NP	SCI	1999
@NP	partial or complete loss	2013
@NP	motor , sensory and autonomic neural functions	2041
@NP	the injury level	2093
@NP	the damage	2118
@NP	local circuitry of the spinal cord	2132
@NP	local circuitry	2132
@NP	the spinal cord	2151
@NP	the interruption of ascending and descending neural pathways	2172
@NP	the interruption	2172
@NP	neural pathways	2217
@NP	the search	2237
@NP	potential treatments	2252
@NP	repair and recovery	2284
@NP	the injury	2309
@NP	cell-based therapies	2321
@NP	beneficial effects	2360
@NP	different types	2385
@NP	cells	2404
@NP	pre-clinical models	2413
@NP	Sykov	2434
@NP	a et al. , 2006	2440
@NP	a et al.	2440
@NP	2006	2450
@NP	Sahni & Kessler , 2010	2456
@NP	Sahni & Kessler	2456
@NP	2010	2473
@NP	Hern andez et al. , 2011	2479
@NP	Hern andez	2479
@NP	et al. , 2011	2490
@NP	et al.	2490
@NP	2011	2498
@NP	Mothe & Tator , 2012	2504
@NP	Mothe & Tator	2504
@NP	2012	2519
@NP	Two	2526
@NP	the most	2533
@NP	cells	2562
@NP	SCI repair	2577
@NP	experimental models	2591
@NP	good perspectives for clinical translation	2620
@NP	good perspectives	2620
@NP	clinical translation	2642
@NP	bone marrow mesenchymal stromal cells -LRB- MSCs -RRB-	2667
@NP	bone marrow mesenchymal stromal cells	2667
@NP	MSCs	2706
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	2716
@NP	olfactory ensheathing cells	2716
@NP	OECs	2745
@NP	Olfactory ensheathing cells	3782
@NP	glial cells present in the olfactory system	3814
@NP	glial cells	3814
@NP	the olfactory system	3837
@NP	Their function	3859
@NP	the elongation of newly growing sensory axons	3898
@NP	the elongation	3898
@NP	newly growing sensory axons	3916
@NP	the olfactory epithelium	3949
@NP	the central olfactory bulb	3977
@NP	axons	4011
@NP	new synaptic connections -LRB- Raisman , 1985 ; Doucette , 1995 -RRB-	4022
@NP	new synaptic connections	4022
@NP	Raisman , 1985 ; Doucette , 1995	4048
@NP	Raisman	4048
@NP	1985 ; Doucette	4057
@NP	1985	4057
@NP	Doucette	4063
@NP	1995	4073
@NP	Acute transplantation of OECs into partial or complete spinal cord lesions	4080
@NP	Acute transplantation	4080
@NP	OECs into partial or complete spinal cord lesions	4105
@NP	OECs	4105
@NP	partial or complete spinal cord lesions	4115
@NP	the volume of injured tissue	4163
@NP	the volume	4163
@NP	injured tissue	4177
@NP	improvement	4201
@NP	functional outcome	4216
@NP	axonal regeneration	4248
@NP	Li et al. , 1998 ; Lu et al. , 2002 ; Verd u et al. , 2003	4269
@NP	Li	4269
@NP	et al. , 1998 ; Lu et al. , 2002 ; Verd u et al. , 2003	4272
@NP	et al. , 1998	4272
@NP	et al.	4272
@NP	1998	4280
@NP	Lu et al. , 2002	4286
@NP	Lu	4286
@NP	et al. , 2002	4289
@NP	et al.	4289
@NP	2002	4297
@NP	Verd u et al. , 2003	4303
@NP	Verd u	4303
@NP	et al. , 2003	4310
@NP	et al.	4310
@NP	2003	4318
@NP	Garc ıa-Al	4324
@NP	et al. , 2004 ; L opez-Vales et al. , 2006	4339
@NP	et al. , 2004	4339
@NP	et al.	4339
@NP	2004	4347
@NP	L opez-Vales et al. , 2006	4353
@NP	L opez-Vales	4353
@NP	et al. , 2006	4366
@NP	et al.	4366
@NP	2006	4374
@NP	the objective of this work	5385
@NP	the objective	5385
@NP	this work	5402
@NP	the effects on tissue protection	5427
@NP	the effects	5427
@NP	tissue protection	5442
@NP	functional recovery of MSC or OEC transplantation	5464
@NP	functional recovery	5464
@NP	MSC or OEC transplantation	5487
@NP	a contusive SCI	5520
@NP	the same animal model , assessment methodologies and culture conditions ,	5543
@NP	the same animal model	5543
@NP	assessment methodologies and culture conditions	5566
@NP	assessment methodologies	5566
@NP	culture conditions	5595
@NP	the same experimenters	5618
@NP	The results	5642
@NP	the knowledge	5679
@NP	the best option for cell therapy of the contused spinal cord	5706
@NP	the best option	5706
@NP	cell therapy of the contused spinal cord	5726
@NP	cell therapy	5726
@NP	the contused spinal cord	5742
@NP	the	5742
@NP	spinal cord	5755
@NP	Materials and methods	5769
@NP	Materials	5769
@NP	methods	5783
@NP	Primary cell cultures	5791
@NP	Primary cultures of MSCs and OECs	5813
@NP	Primary cultures	5813
@NP	MSCs and OECs	5833
@NP	P22 male Sprague	5864
@NP	Dawley rats	5881
@NP	The animals	5894
@NP	CO2	5923
@NP	each animal	5933
@NP	tibias and femurs	5945
@NP	MSC culture and the olfactory bulbs	5980
@NP	MSC culture	5980
@NP	the olfactory bulbs	5996
@NP	OEC culture	6020
@NP	MSC culture and characterization Tibias and femurs	6033
@NP	cool phosphate-buffered saline -LRB- PBS -RRB-	6099
@NP	cool phosphate-buffered saline	6099
@NP	PBS	6131
@NP	epiphyses	6140
@NP	The diaphyses of bones	6164
@NP	The diaphyses	6164
@NP	bones	6181
@NP	PBS	6205
@NP	a syringe	6215
@NP	the marrow	6229
@NP	The extract	6257
@NP	a 70-µm nylon mesh	6290
@NP	centrifugation for 10 min	6326
@NP	centrifugation	6326
@NP	10 min	6345
@NP	220 g.	6355
@NP	The pellet	6362
@NP	growth medium	6392
@NP	a-minimum essential medium -LRB- MEM -RRB-	6408
@NP	a-minimum essential medium	6408
@NP	MEM	6436
@NP	L-glutamine	6446
@NP	Life Technologies	6459
@NP	Grand Island	6478
@NP	NY , USA	6492
@NP	20 % heat-inactivated fetal bovine serum	6519
@NP	20 %	6519
@NP	FBS ; Lonza , Verviers , Belgium	6560
@NP	FBS	6560
@NP	Lonza , Verviers , Belgium	6565
@NP	2 mM L-glutamine -LRB- Life Technologies -RRB-	6592
@NP	2 mM L-glutamine	6592
@NP	Life Technologies	6610
@NP	100 units/mL penicillin-streptomycin -LRB- Life Technologies ; 100 9 -RRB-	6633
@NP	100 units/mL penicillin-streptomycin	6633
@NP	Life Technologies ; 100 9	6671
@NP	Life Technologies	6671
@NP	100 9	6690
@NP	100-mm culture dishes -LRB- Iwaki , Asahi Technoglass , Chiba , Japan -RRB-	6712
@NP	100-mm culture dishes	6712
@NP	Iwaki	6735
@NP	Asahi Technoglass	6742
@NP	Chiba , Japan	6761
@NP	a density of 5 9	6778
@NP	a density	6778
@NP	5 9	6791
@NP	106 cells/cm2	6795
@NP	24 h	6816
@NP	the supernatant containing non-adherent cells	6822
@NP	the supernatant	6822
@NP	non-adherent cells	6849
@NP	fresh medium	6884
@NP	the culture	6913
@NP	confluence , every 4 -- 5 days	6934
@NP	confluence , every 4 --	6934
@NP	confluence	6934
@NP	every 4	6946
@NP	5 days	6954
@NP	the cells	6962
@NP	PBS with 0.05 % trypsin -LRB- Life Technologies -RRB-	6992
@NP	PBS	6992
@NP	0.05 % trypsin -LRB- Life Technologies -RRB-	7001
@NP	0.05 % trypsin	7001
@NP	Life Technologies	7016
@NP	0.04 % Ethylenediaminetetraacetic acid -LRB- Sigma , St Louis , MO , USA -RRB-	7039
@NP	0.04 %	7039
@NP	Ethylenediaminetetraacetic acid -LRB- Sigma , St Louis , MO , USA -RRB-	7045
@NP	Ethylenediaminetetraacetic acid	7045
@NP	Sigma	7078
@NP	St Louis	7085
@NP	MO , USA	7095
@NP	5000 cells/cm2	7122
@NP	Cells	7138
@NP	three -- four times , expanded to 80 -- 90 % of confluence	7158
@NP	three	7158
@NP	four times , expanded to 80 -- 90 % of confluence	7164
@NP	four times , expanded to 80	7164
@NP	four times	7164
@NP	80	7188
@NP	90 % of confluence	7191
@NP	90 %	7191
@NP	confluence	7198
@NP	phenotype characterization	7214
@NP	MSCs after four passages in culture	7242
@NP	MSCs	7242
@NP	four passages in culture	7253
@NP	four passages	7253
@NP	culture	7270
@NP	30 min	7295
@NP	antibodies	7308
@NP	CD90 , CD29 , CD11b and CD45	7327
@NP	FITC	7371
@NP	BD Bioscience , Erembodegem , Belgium	7377
@NP	BD Bioscience	7377
@NP	Erembodegem , Belgium	7392
@NP	1 : 200 v/v	7414
@NP	1	7414
@NP	200 v/v	7418
@NP	incubation	7434
@NP	the cells	7446
@NP	5 min at 160 g	7477
@NP	5 min	7477
@NP	160 g	7486
@NP	PBS	7511
@NP	Analysis of surface markers	7516
@NP	Analysis	7516
@NP	surface markers	7528
@NP	flow citometry -LRB- FACSCalibur , Becton Dickinson -RRB-	7564
@NP	flow citometry	7564
@NP	FACSCalibur	7580
@NP	Becton Dickinson	7593
@NP	FACSDiva software -LRB- BD Bioscience -RRB-	7615
@NP	FACSDiva software	7615
@NP	BD Bioscience	7634
@NP	The capacity of the MSC for differentiation to adipogenic and osteogenic cells	7650
@NP	The capacity	7650
@NP	the MSC for differentiation to adipogenic and osteogenic cells	7666
@NP	the MSC	7666
@NP	differentiation to adipogenic and osteogenic cells	7678
@NP	differentiation	7678
@NP	adipogenic and osteogenic cells	7697
@NP	et al. , 2008	7775
@NP	et al.	7775
@NP	2008	7783
@NP	analysis of adipogenesis	7794
@NP	analysis	7794
@NP	adipogenesis	7806
@NP	cells	7820
@NP	20 min	7841
@NP	4 % paraformaldehyde in phosphate buffer	7853
@NP	4 % paraformaldehyde	7853
@NP	phosphate buffer	7876
@NP	the adipogenic cells	7894
@NP	60 % Oil red O stock solution -LRB- 0.5 % Oil red O in isopropanol ; Sigma -RRB-	7934
@NP	60 % Oil red O stock solution	7934
@NP	60 % Oil	7934
@NP	red O stock solution	7942
@NP	0.5 % Oil red O in isopropanol ; Sigma	7964
@NP	0.5 %	7964
@NP	Oil red O in isopropanol ; Sigma	7969
@NP	Oil red O in isopropanol	7969
@NP	Oil red O	7969
@NP	isopropanol	7982
@NP	Sigma	7995
@NP	15 min	8006
@NP	distilled water	8029
@NP	osteogenic labeling	8050
@NP	cells	8071
@NP	70 % ethanol pre-cooled for 1 h	8094
@NP	70 % ethanol	8094
@NP	1 h	8121
@NP	4 °C	8128
@NP	30 min with 0.1 mg / mL Alizarin red solution -LRB- Sigma -RRB-	8162
@NP	30 min	8162
@NP	0.1 mg / mL Alizarin red solution -LRB- Sigma -RRB-	8174
@NP	0.1 mg / mL Alizarin red solution	8174
@NP	mL Alizarin red solution	8182
@NP	mL	8182
@NP	Alizarin red solution	8185
@NP	Sigma	8208
@NP	distilled water	8218
@NP	OEC culture and characterization Olfactory bulbs	8235
@NP	cold Hank 's balanced salt solution -LRB- Sigma -RRB-	8323
@NP	cold Hank 's balanced salt solution	8323
@NP	cold Hank 's	8323
@NP	Sigma	8359
@NP	calcium and magnesium	8371
@NP	The meningeal layer	8394
@NP	a fine forceps	8436
@NP	tissue	8456
@NP	trypsin	8482
@NP	0.25 % ; collagenase A 1 mg/mL ; Becton Dickinson	8490
@NP	0.25 %	8490
@NP	collagenase A 1 mg/mL	8497
@NP	collagenase A	8497
@NP	1 mg/mL	8511
@NP	Becton Dickinson	8520
@NP	DNAsa	8538
@NP	I 1 mg/mL ; Roche , Barcelona , Spain	8544
@NP	I 1 mg/mL	8544
@NP	I	8544
@NP	1 mg/mL	8546
@NP	Roche , Barcelona , Spain	8555
@NP	Roche	8555
@NP	Barcelona , Spain	8562
@NP	The cells	8610
@NP	centrifugation	8638
@NP	Dulbecco 's -LRB- D -RRB- MEM nutrient	8656
@NP	Dulbecco 's	8656
@NP	D	8668
@NP	mixture F-12 Ham -LRB- Life Technologies -RRB-	8683
@NP	mixture F-12 Ham	8683
@NP	Life Technologies	8701
@NP	25-cm2 flasks coated with poly-L-lysine and incubated in 5 % CO2 at 37 °C	8736
@NP	25-cm2 flasks	8736
@NP	poly-L-lysine	8762
@NP	5 % CO2 at 37 °C	8793
@NP	5 % CO2	8793
@NP	37 °C	8803
@NP	Culture medium	8810
@NP	DMEM supplemented with 10 % FBS -LRB- Life Technologies -RRB-	8829
@NP	DMEM	8829
@NP	10 % FBS -LRB- Life Technologies -RRB-	8852
@NP	10 % FBS	8852
@NP	Life Technologies	8861
@NP	Cells	8881
@NP	culture	8900
@NP	7 days	8921
@NP	purification	8933
@NP	the cells	8947
@NP	mouse anti-p75NGFR antibody -LRB- 1 : 100 ; Millipore , Billerica , MA , USA	8977
@NP	mouse anti-p75NGFR antibody	8977
@NP	1 : 100 ; Millipore , Billerica , MA , USA	9006
@NP	1 : 100	9006
@NP	Millipore , Billerica , MA , USA	9015
@NP	ref	9046
@NP	then	9060
@NP	goat antimouse IgG microbeads -LRB- Miltenyi Biotec , Madrid , Spain -RRB-	9085
@NP	goat antimouse IgG microbeads	9085
@NP	Miltenyi Biotec	9116
@NP	Madrid	9133
@NP	Spain	9141
@NP	the MACS separation -LRB- Miltenyi Biotec -RRB-	9154
@NP	the MACS separation	9154
@NP	Miltenyi Biotec	9175
@NP	OEC purity	9193
@NP	at least 75 % determined by immunolabeling against p75 and S100	9208
@NP	at least 75 %	9208
@NP	immunolabeling against p75 and S100	9235
@NP	immunolabeling	9235
@NP	p75 and S100	9258
@NP	immunocytochemistry	9276
@NP	OEC cultures	9297
@NP	4 % paraformaldehyde	9326
@NP	PBS	9349
@NP	30 min	9357
@NP	24 h with primary antibodies mouse anti-p75NGFR and rabbit anti-S100	9384
@NP	24 h	9384
@NP	primary antibodies mouse anti-p75NGFR and rabbit anti-S100	9394
@NP	1 : 200 ; DiaSorin , Madrid , Spain	9454
@NP	1 : 200	9454
@NP	DiaSorin , Madrid , Spain	9463
@NP	1 h	9521
@NP	secondary antibodies	9530
@NP	Cy3-conjugated donkey anti-mouse	9551
@NP	1 : 200 ; Jackson ImmunoResearch	9585
@NP	1 : 200	9585
@NP	Jackson ImmunoResearch	9594
@NP	West Grove , PA , USA	9618
@NP	West Grove	9618
@NP	PA	9630
@NP	USA	9634
@NP	Alexa 488 donkey anti-rabbit -LRB- 1 : 200 ; Life Technologies -RRB-	9642
@NP	Alexa 488 donkey	9642
@NP	anti-rabbit -LRB- 1 : 200 ; Life Technologies -RRB-	9659
@NP	anti-rabbit	9659
@NP	1 : 200 ; Life Technologies	9672
@NP	1 : 200	9672
@NP	Life Technologies	9681
@NP	Cell labeling	9701
@NP	identification of the cells after grafting	9719
@NP	identification	9719
@NP	the cells after grafting	9737
@NP	the cells	9737
@NP	grafting	9753
@NP	we	9763
@NP	a green fluorescence protein -LRB- GFP -RRB- lentiviral vector	9771
@NP	green fluorescence protein -LRB- GFP -RRB-	9773
@NP	green fluorescence protein	9773
@NP	GFP	9801
@NP	MSCs	9825
@NP	a lentiviral vector encoding for GFP under EF1a promoter	9852
@NP	a lentiviral vector	9852
@NP	GFP	9885
@NP	EF1a promoter	9895
@NP	Cells in passage 2	9910
@NP	Cells	9910
@NP	passage 2	9919
@NP	2000 cells/cm2	9944
@NP	lentiviruses at multiplicity of infection of 10	9978
@NP	lentiviruses	9978
@NP	multiplicity of infection of 10	9994
@NP	multiplicity	9994
@NP	infection of 10	10010
@NP	infection	10010
@NP	10	10023
@NP	48 h.	10033
@NP	the medium	10045
@NP	the cells	10072
@NP	OEC transduction was done at 2	10111
@NP	OEC transduction	10111
@NP	2	10140
@NP	3 days of selection at multiplicity of infection of 50 for 24 h.	10142
@NP	3 days	10142
@NP	selection at multiplicity of infection of 50	10152
@NP	selection	10152
@NP	multiplicity of infection of 50	10165
@NP	multiplicity	10165
@NP	infection of 50	10181
@NP	infection	10181
@NP	50	10194
@NP	24 h.	10201
@NP	the medium	10212
@NP	complete culture medium and the cells cultured for five more days	10239
@NP	complete culture medium	10239
@NP	the cells cultured for five more days	10267
@NP	the cells	10267
@NP	five more days	10290
@NP	96 % of transfection	10312
@NP	96 %	10312
@NP	transfection	10319
@NP	efficacy	10332
@NP	flow cytometry and fluorescence microscopy counting for both OEC and MSC cells	10359
@NP	flow cytometry and fluorescence microscopy	10359
@NP	both OEC and MSC cells	10415
@NP	SCI and cells transplantation Adult female Sprague -- Dawley rats	10439
@NP	SCI	10439
@NP	cells transplantation Adult	10447
@NP	female Sprague	10475
@NP	Dawley rats	10490
@NP	Dawley	10490
@NP	rats	10497
@NP	9 weeks old ; 250 -- 300 g	10503
@NP	9 weeks old	10503
@NP	250 -- 300 g	10516
@NP	250	10516
@NP	300 g	10520
@NP	The animals	10538
@NP	free access	10567
@NP	food and water	10582
@NP	room temperature of 22 2 °C	10600
@NP	room temperature	10600
@NP	22 2 °C	10620
@NP	The experimental procedures	10631
@NP	the ethical committee	10676
@NP	the Universitat Aut onoma	10701
@NP	Barcelona in accordance with the European Communities	10730
@NP	Barcelona	10730
@NP	accordance with the European Communities	10743
@NP	accordance	10743
@NP	the European Communities	10759
@NP	Council Directive 86/609/EEC	10784
@NP	Operations	10814
@NP	ketamine/xylazine anesthesia -LRB- 90/10 mg/kg i.p. -RRB-	10846
@NP	ketamine/xylazine anesthesia	10846
@NP	90/10 mg/kg	10876
@NP	subcutaneous injection of buprenorphine -LRB- 0.05 mg/kg -RRB-	10904
@NP	subcutaneous injection	10904
@NP	buprenorphine -LRB- 0.05 mg/kg -RRB-	10930
@NP	buprenorphine	10930
@NP	0.05 mg/kg	10945
@NP	the incision site	10960
@NP	A longitudinal dorsal incision	10979
@NP	T6 -- T10 spinous processes	11029
@NP	T6	11029
@NP	T10 spinous processes	11032
@NP	T10	11032
@NP	spinous processes	11036
@NP	A laminectomy	11055
@NP	T8 -- T9 vertebra	11086
@NP	T8	11086
@NP	T9 vertebra	11089
@NP	a cord contusion of 200 Kdyn	11106
@NP	a cord contusion	11106
@NP	200 Kdyn	11126
@NP	an Infinite Horizon Impactor	11153
@NP	Precision System and Instrumentation , Kentucky , USA	11183
@NP	Precision System	11183
@NP	Instrumentation , Kentucky , USA	11204
@NP	the study of treatment effects	11241
@NP	the study	11241
@NP	treatment effects	11254
@NP	the animals	11273
@NP	six groups	11303
@NP	Three groups of rats	11315
@NP	Three groups	11315
@NP	rats	11331
@NP	30 min after operation	11363
@NP	30 min	11363
@NP	operation	11376
@NP	0 days post-operation -LRB- dpo -RRB- -RSB-	11387
@NP	0 days	11387
@NP	dpo	11410
@NP	vehicle -LRB- VE -- 0 dpo , n = 8 rats -RRB-	11422
@NP	vehicle	11422
@NP	VE	11431
@NP	0 dpo , n = 8 rats	11434
@NP	0 dpo	11434
@NP	n = 8 rats	11441
@NP	n	11441
@NP	8 rats	11445
@NP	MSC -LRB- MSC -- 0 dpo , n = 8 rats -RRB-	11459
@NP	MSC	11459
@NP	MSC	11464
@NP	0 dpo , n = 8 rats	11468
@NP	0 dpo	11468
@NP	n = 8 rats	11475
@NP	n	11475
@NP	8 rats	11479
@NP	OEC -LRB- OEC -- 0 dpo , n = 8 rats -RRB-	11495
@NP	OEC	11495
@NP	OEC	11500
@NP	0 dpo , n = 8 rats	11505
@NP	0 dpo	11505
@NP	n = 8 rats	11512
@NP	n	11512
@NP	8 rats	11516
@NP	Another three groups of rats	11525
@NP	Another three groups	11525
@NP	rats	11549
@NP	7 dpo	11575
@NP	vehicle -LRB- VE -- 7 dpo , n = 7 rats -RRB-	11586
@NP	vehicle	11586
@NP	VE	11595
@NP	7 dpo , n = 7 rats	11598
@NP	7 dpo	11598
@NP	n = 7 rats	11605
@NP	n	11605
@NP	7 rats	11609
@NP	MSC -LRB- MSC -- 7 dpo , n = 7 rats -RRB-	11618
@NP	MSC	11618
@NP	MSC	11623
@NP	7 dpo , n = 7 rats	11627
@NP	7 dpo	11627
@NP	n = 7 rats	11634
@NP	n	11634
@NP	7 rats	11638
@NP	OEC -LRB- OEC -- 7 dpo , n = 7 rats -RRB-	11649
@NP	OEC	11649
@NP	OEC	11654
@NP	7 dpo , n = 7 rats	11658
@NP	7 dpo	11658
@NP	n = 7 rats	11665
@NP	n	11665
@NP	7 rats	11669
@NP	assessment of cell localization after grafting	11682
@NP	assessment	11682
@NP	cell localization after grafting	11696
@NP	cell localization	11696
@NP	grafting	11720
@NP	GFP-labeled cells -LRB- gMSC or gOEC -RRB-	11730
@NP	GFP-labeled cells	11730
@NP	gMSC or gOEC	11749
@NP	gMSC	11749
@NP	gOEC	11757
@NP	transplanted	11768
@NP	acutely or 7 days post-lesion in the corresponding groups gMSC	11788
@NP	7 days	11799
@NP	the corresponding groups	11821
@NP	0 dpo -LRB- n = 9 rats -RRB- , gOEC	11851
@NP	0 dpo -LRB- n = 9 rats -RRB-	11851
@NP	n	11858
@NP	9 rats	11862
@NP	gOEC	11871
@NP	0 dpo -LRB- n = 9 rats -RRB- , gMSC	11876
@NP	0 dpo -LRB- n = 9 rats -RRB-	11876
@NP	n	11883
@NP	9 rats	11887
@NP	gMSC	11896
@NP	7 dpo -LRB- n = 9 rats -RRB-	11901
@NP	n	11908
@NP	9 rats	11912
@NP	gOEC -- 7 dpo -LRB- n = 9 rats -RRB-	11924
@NP	gOEC	11924
@NP	7 dpo -LRB- n = 9 rats -RRB-	11929
@NP	n	11936
@NP	9 rats	11940
@NP	The cells for transplantation	11949
@NP	The cells	11949
@NP	transplantation	11963
@NP	L15 medium -LRB- Life Technologies -RRB- at 50 000 cells/lL	11997
@NP	L15 medium -LRB- Life Technologies -RRB-	11997
@NP	L15 medium	11997
@NP	Life Technologies	12009
@NP	50 000 cells/lL	12031
@NP	ice	12065
@NP	the time of surgery	12076
@NP	the time	12076
@NP	surgery	12088
@NP	The cell viability at the time of injection	12097
@NP	The cell viability	12097
@NP	the time of injection	12119
@NP	the time	12119
@NP	injection	12131
@NP	90 % , as quantified in a Neubauer chamber using trypan blue stain	12151
@NP	90 %	12151
@NP	a Neubauer chamber	12173
@NP	trypan blue	12198
@NP	a glass needle	12223
@NP	100 µm	12239
@NP	internal diameter ; Eppendorf , Hamburg , Germany	12246
@NP	internal diameter	12246
@NP	Eppendorf , Hamburg , Germany	12265
@NP	a 10-lL Hamilton syringe -LRB- Hamilton # 701 ; Hamilton , Reno , NV , USA -RRB-	12305
@NP	a 10-lL Hamilton syringe	12305
@NP	Hamilton	12331
@NP	# 701 ; Hamilton , Reno , NV , USA	12340
@NP	# 701	12340
@NP	Hamilton , Reno , NV , USA	12346
@NP	3 lL of the corresponding cell suspension or vehicle -LRB- L15 -RRB-	12372
@NP	3 lL	12372
@NP	the corresponding cell suspension or vehicle -LRB- L15 -RRB-	12380
@NP	the corresponding cell suspension or vehicle	12380
@NP	L15	12426
@NP	the epicenter	12461
@NP	2 mm	12482
@NP	a total of 450 000 cells per rat	12515
@NP	a total	12515
@NP	450 000 cells per rat	12526
@NP	450 000 cells	12526
@NP	rat	12544
@NP	A perfusion speed of 2 lL/min	12549
@NP	A perfusion speed	12549
@NP	2 lL/min	12570
@NP	an automatic injector	12597
@NP	KDS 310 Plus , Kd Scientific , Holliston , MA , USA	12620
@NP	KDS 310 Plus	12620
@NP	Kd Scientific	12634
@NP	Holliston	12649
@NP	MA	12660
@NP	USA	12664
@NP	the needle tip	12674
@NP	the tissue 3 min	12711
@NP	each injection to avoid liquid reflux	12734
@NP	liquid reflux	12758
@NP	The wound	12773
@NP	the animals	12799
@NP	a warm environment	12833
@NP	Bladders	12853
@NP	twice a day	12877
@NP	reflex voiding of the bladder	12895
@NP	reflex voiding	12895
@NP	the bladder	12913
@NP	infection	12955
@NP	amoxicillin -LRB- 500 mg/L -RRB-	12966
@NP	amoxicillin	12966
@NP	500 mg/L	12979
@NP	the drinking water for 1	13002
@NP	the drinking water	13002
@NP	1	13025
@NP	week	13027
@NP	Locomotor and sensory function assessment Open-field locomotion Motor behavior	13033
@NP	Locomotor	13033
@NP	sensory function assessment Open-field locomotion Motor behavior	13047
@NP	sensory function assessment	13047
@NP	Open-field locomotion Motor behavior	13075
@NP	surgery , and at 3 , 7 , 14 , 21 , 28 , 35 and 42 dpo	13130
@NP	surgery	13130
@NP	3	13146
@NP	7	13149
@NP	14	13152
@NP	21	13156
@NP	28	13160
@NP	35	13164
@NP	42 dpo	13171
@NP	Animals	13179
@NP	a circular enclosure	13215
@NP	5 min	13267
@NP	Two observers	13274
@NP	locomotion	13298
@NP	open-field walking	13316
@NP	the hindlimb performance	13347
@NP	Basso , Beattie and Bresnahan	13390
@NP	BBB	13420
@NP	scale	13425
@NP	0 -LRB- no movement -RRB-	13445
@NP	0	13445
@NP	no movement	13448
@NP	21 -LRB- normal movement ; Basso et al. , 1995 -RRB-	13464
@NP	21	13464
@NP	normal movement ; Basso et al. , 1995	13468
@NP	normal movement	13468
@NP	Basso et al. , 1995	13485
@NP	Basso	13485
@NP	et al. , 1995	13491
@NP	et al.	13491
@NP	1995	13499
@NP	Treadmill locomotion	13506
@NP	The maximal walking speed	13527
@NP	gait motion and interlimb coordination	13554
@NP	the end time point	13596
@NP	treadmill conditions	13635
@NP	a Digigait Imaging system	13662
@NP	Mouse Specifics	13689
@NP	Boston	13706
@NP	MA , USA	13714
@NP	Redondo-Castro et al. , 2013	13748
@NP	Redondo-Castro	13748
@NP	et al.	13763
@NP	2013	13771
@NP	a highspeed video camera	13787
@NP	a transparent treadmill belt	13826
@NP	ventral images of the animal	13864
@NP	ventral images	13864
@NP	the animal	13882
@NP	140 frames/s	13896
@NP	a minimum of eight sequential step cycles	13914
@NP	a minimum	13914
@NP	eight sequential step cycles	13927
@NP	the maximal speed analysis	13975
@NP	the treadmill speed	14003
@NP	0 cm/s	14056
@NP	the animal	14069
@NP	the selected speed	14103
@NP	gait and interlimb coordination	14127
@NP	the animals	14160
@NP	20 cm/s	14189
@NP	the animals	14206
@NP	this speed	14238
@NP	The videos	14250
@NP	elsewhere -LRB- Redondo-Castro et al. , 2013 -RRB-	14288
@NP	elsewhere	14288
@NP	Redondo-Castro	14299
@NP	et al. , 2013	14314
@NP	et al.	14314
@NP	2013	14322
@NP	The start	14329
@NP	times of the stance phase of each step	14350
@NP	times	14350
@NP	the stance phase of each step	14359
@NP	the stance phase	14359
@NP	each step	14379
@NP	the videos	14417
@NP	ImageJ software -LRB- NIH , Bethesda MA , USA -RRB-	14434
@NP	ImageJ software	14434
@NP	NIH	14451
@NP	Bethesda MA	14456
@NP	USA	14469
@NP	foot gait diagram	14479
@NP	McEwen & Springer	14511
@NP	2006	14530
@NP	Quantitative values	14537
@NP	the gait parameters	14561
@NP	stride duration , stance duration and swing duration	14582
@NP	stride duration	14582
@NP	stance duration and swing duration	14599
@NP	the stance/swing ratio	14639
@NP	a Visual Basic macro for Excel software -LRB- Microsoft -RRB-	14684
@NP	a Visual Basic macro	14684
@NP	Excel software -LRB- Microsoft -RRB-	14709
@NP	Excel software	14709
@NP	Microsoft	14726
@NP	the values previously extracted	14742
@NP	the values	14742
@NP	the coordination of locomotion	14785
@NP	the coordination	14785
@NP	locomotion	14805
@NP	the regularity index -LRB- RI -RRB-	14817
@NP	the regularity index	14817
@NP	RI	14839
@NP	A regular step pattern	14859
@NP	locomotion , in which each paw is exactly placed one time every four footprints	14908
@NP	locomotion , in which each paw is exactly placed one time	14908
@NP	locomotion	14908
@NP	each paw	14929
@NP	one time	14956
@NP	every four footprints	14965
@NP	a given time	15015
@NP	The RI	15029
@NP	the percentage of correct step sequences	15053
@NP	the percentage	15053
@NP	correct step sequences	15071
@NP	respect	15099
@NP	the total number of step cycles	15110
@NP	the total number	15110
@NP	step cycles	15130
@NP	the lower the RI , the larger	15149
@NP	the lower the RI	15149
@NP	the lower	15149
@NP	the RI	15159
@NP	the larger	15167
@NP	the number of missteps	15178
@NP	the number	15178
@NP	missteps	15192
@NP	the correct pattern	15215
@NP	Cheng et al. , 1997 ; Hamers et al. , 2006	15236
@NP	Cheng	15236
@NP	et al. , 1997 ; Hamers et al. , 2006	15242
@NP	et al. , 1997	15242
@NP	et al.	15242
@NP	1997	15250
@NP	Hamers et al. , 2006	15256
@NP	Hamers	15256
@NP	et al. , 2006	15263
@NP	et al.	15263
@NP	2006	15271
@NP	Sensory tests	15278
@NP	surgery	15314
@NP	42 dpo	15329
@NP	hindpaws	15344
@NP	The rats	15354
@NP	the testing chamber for 10 min	15382
@NP	the testing chamber	15382
@NP	10 min	15406
@NP	The response to mechanical stimuli	15414
@NP	The response	15414
@NP	mechanical stimuli	15430
@NP	an electronic Von Frey algesimeter -LRB- Bioseb , Chaville , France -RRB-	15466
@NP	an electronic Von Frey algesimeter	15466
@NP	Bioseb	15502
@NP	Chaville	15510
@NP	France	15520
@NP	The spring metallic filament connected to a force sensor	15529
@NP	The spring metallic filament	15529
@NP	a force sensor	15571
@NP	the medial part of the hindpaw	15601
@NP	the medial part	15601
@NP	the hindpaw	15620
@NP	the pressure	15633
@NP	the threshold	15671
@NP	the force at which the animal withdrew the paw	15703
@NP	the force	15703
@NP	the animal	15722
@NP	the paw	15742
@NP	The response to heat stimuli	15751
@NP	The response	15751
@NP	heat stimuli	15767
@NP	a Plantar algesimeter -LRB- Ugo Basile , Comerio , Italy -RRB-	15804
@NP	a Plantar algesimeter	15804
@NP	Ugo Basile	15827
@NP	Comerio	15839
@NP	Italy	15848
@NP	The rats	15856
@NP	a radiant hot stimulus	15874
@NP	the hindpaw , and the latency time	15900
@NP	the hindpaw	15900
@NP	the latency time	15917
@NP	the animal	15940
@NP	the limb	15960
@NP	the hot pain threshold	15991
@NP	A cut-off time	16015
@NP	20 s	16041
@NP	tissue damage	16057
@NP	Five trials separated by 10-min resting periods for each hindpaw	16072
@NP	Five trials	16072
@NP	10-min resting periods for each hindpaw	16097
@NP	10-min resting periods	16097
@NP	each hindpaw	16124
@NP	both sensory tests	16155
@NP	The value for each test	16175
@NP	The value	16175
@NP	each test	16189
@NP	the mean of both hindpaws	16203
@NP	the mean	16203
@NP	both hindpaws	16215
@NP	Electrophysiological studies	16230
@NP	the electrophysiological tests	16263
@NP	the animals	16294
@NP	30 mg/kg	16344
@NP	a metal plate and skin temperature	16378
@NP	32 °C	16430
@NP	An electromyograph -LRB- Sapphire 4ME , Vickers -RRB-	16437
@NP	An electromyograph	16437
@NP	Sapphire 4ME	16457
@NP	Vickers	16471
@NP	Central conduction tests	16490
@NP	the evaluation of motorevoked potentials -LRB- MEPs -RRB-	16528
@NP	the evaluation	16528
@NP	motorevoked potentials -LRB- MEPs -RRB-	16546
@NP	motorevoked potentials	16546
@NP	MEPs	16570
@NP	MEPs	16577
@NP	transcranial electrical stimulation of the brain	16599
@NP	transcranial electrical stimulation	16599
@NP	the brain	16638
@NP	Two needle electrodes	16649
@NP	the skull , the anode over the sensorimotor cortex and the cathode on the nose	16703
@NP	the skull	16703
@NP	the anode over the sensorimotor cortex	16714
@NP	the anode	16714
@NP	the sensorimotor cortex	16729
@NP	the cathode on the nose	16757
@NP	the cathode	16757
@NP	the nose	16772
@NP	Single electrical pulses of supramaximal intensity -LRB- 25 mA , 100 ls -RRB-	16782
@NP	Single electrical pulses	16782
@NP	supramaximal intensity -LRB- 25 mA , 100 ls -RRB-	16810
@NP	supramaximal intensity	16810
@NP	25 mA	16834
@NP	100 ls	16841
@NP	the MEPs	16867
@NP	monopolar needle electrodes	16895
@NP	the tibialis anterior -LRB- TA -RRB-	16928
@NP	the tibialis anterior	16928
@NP	TA	16951
@NP	gastrocnemius medialis -LRB- GM -RRB-	16956
@NP	gastrocnemius medialis	16956
@NP	plantar -LRB- PL -RRB- muscles	16988
@NP	plantar -LRB- PL -RRB-	16988
@NP	muscles	17001
@NP	Garc ıa-Al	17010
@NP	et al. , 2004 ; Valero-Cabr e et al. , 2004	17025
@NP	et al.	17025
@NP	2004 ; Valero-Cabr e et al.	17033
@NP	2004	17033
@NP	Valero-Cabr e et al.	17039
@NP	Valero-Cabr	17039
@NP	et al.	17053
@NP	2004	17061
@NP	Peripheral motor nerve conduction tests	17068
@NP	the sciatic nerve	17138
@NP	single electrical pulses	17161
@NP	100 ls at supramaximal intensity	17187
@NP	100 ls	17187
@NP	supramaximal intensity	17197
@NP	needles inserted percutaneously at the sciatic notch	17234
@NP	needles	17234
@NP	the sciatic notch	17269
@NP	the compound muscle action potentials of TA , GM and PL muscles	17302
@NP	the compound muscle action potentials	17302
@NP	TA , GM and PL muscles	17343
@NP	TA	17343
@NP	GM	17347
@NP	PL muscles	17354
@NP	means of needle electrodes	17368
@NP	means	17368
@NP	needle electrodes	17377
@NP	The active electrode	17396
@NP	the belly of the muscle and the reference	17433
@NP	the belly	17433
@NP	the muscle and the reference	17446
@NP	the muscle	17446
@NP	the reference	17461
@NP	the fourth toe	17478
@NP	The direct M-wave and the reflex H-wave	17494
@NP	The direct M-wave	17494
@NP	the reflex H-wave	17516
@NP	electrophysiological analog of the stretch reflex	17535
@NP	electrophysiological analog	17535
@NP	the stretch reflex	17566
@NP	the same sweep	17603
@NP	The peak latency and the onset-to-peak amplitude of the maximal M - and H-waves	17619
@NP	The peak latency	17619
@NP	the onset-to-peak amplitude of the maximal M - and H-waves	17640
@NP	the onset-to-peak amplitude	17640
@NP	the maximal M - and H-waves	17671
@NP	the maximal M	17671
@NP	H-waves	17690
@NP	The H/M amplitude ratio	17713
@NP	it	17761
@NP	an index	17773
@NP	the proportion	17785
@NP	motor units	17803
@NP	the monosynaptic reflex relative	17828
@NP	the total pool	17864
@NP	spinal motoneurons	17882
@NP	Thompson	17902
@NP	et al. , 1992 ; Valero-Cabr e et al. , 2004	17911
@NP	et al.	17911
@NP	1992 ; Valero-Cabr e et al.	17919
@NP	1992	17919
@NP	Valero-Cabr e et al.	17925
@NP	Valero-Cabr	17925
@NP	et al.	17939
@NP	2004	17947
@NP	Histology	17954
@NP	Tissue processing	17964
@NP	The end time point of the animals for treatment study	17982
@NP	The end time point	17982
@NP	the animals for treatment study	18004
@NP	the animals	18004
@NP	treatment study	18020
@NP	42 days after injury	18040
@NP	42 days	18040
@NP	injury	18054
@NP	cell tracking	18066
@NP	subgroups of animals injected with gMSC or gOEC	18081
@NP	subgroups	18081
@NP	animals injected with gMSC or gOEC	18094
@NP	animals	18094
@NP	gMSC or gOEC	18116
@NP	7 , 14 and 21	18144
@NP	days	18157
@NP	injection	18168
@NP	n = 3 for each time point	18179
@NP	n = 3	18179
@NP	n	18179
@NP	3	18183
@NP	each time point	18189
@NP	The rats	18207
@NP	pentobarbital 60 mg/kg i.p.	18242
@NP	pentobarbital	18242
@NP	60 mg/kg i.p.	18256
@NP	60 mg/kg	18256
@NP	4 % paraformaldehyde in PBS	18304
@NP	4 % paraformaldehyde	18304
@NP	PBS	18327
@NP	The spinal cord segment from 1 cm rostral to 1 cm caudal of the injury epicenter	18332
@NP	The spinal cord segment	18332
@NP	1 cm rostral to 1 cm caudal of the injury epicenter	18361
@NP	1 cm rostral	18361
@NP	1 cm caudal of the injury epicenter	18377
@NP	1 cm caudal	18377
@NP	the injury epicenter	18392
@NP	2 cm total length	18414
@NP	2 cm	18414
@NP	total length	18419
@NP	the same fixative solution for 4 h	18465
@NP	the same fixative solution	18465
@NP	4 h	18496
@NP	30 % sucrose	18521
@NP	evaluation of the injury	18538
@NP	evaluation	18538
@NP	the injury	18552
@NP	transversal spinal cord sections 30 µm thick	18564
@NP	transversal spinal cord sections	18564
@NP	30 µm	18597
@NP	a cryotome -LRB- Leica CM190 ; Leica Microsystems , Wetzlar , Germany -RRB-	18623
@NP	a cryotome	18623
@NP	Leica CM190 ; Leica Microsystems	18635
@NP	Leica CM190	18635
@NP	Leica Microsystems	18648
@NP	Wetzlar , Germany	18668
@NP	Wetzlar	18668
@NP	Germany	18677
@NP	15 series of 24 sections -LRB- separated by 450 µm -RRB-	18705
@NP	15 series	18705
@NP	24 sections -LRB- separated by 450 µm -RRB-	18718
@NP	24 sections	18718
@NP	450 µm	18744
@NP	each	18752
@NP	cell survival study	18762
@NP	30-µm-thick longitudinal sections of the spinal cord segment	18783
@NP	30-µm-thick longitudinal sections	18783
@NP	the spinal cord segment	18820
@NP	12 series of eight sections -LRB- separated by 360 µm -RRB-	18872
@NP	12 series	18872
@NP	eight sections -LRB- separated by 360 µm -RRB-	18885
@NP	eight sections	18885
@NP	360 µm	18914
@NP	Sections	18928
@NP	gelatincoated glass slides	18957
@NP	Hematoxylin-eosin staining	18985
@NP	One series of 24 transverse sections	19012
@NP	One series	19012
@NP	24 transverse sections	19026
@NP	5 min in water	19069
@NP	5 min	19069
@NP	water	19078
@NP	hematoxylin Harris solution	19103
@NP	the manufacturer 's instructions -LRB- Fluka , Sigma -RRB- for 5 min	19144
@NP	the manufacturer 's instructions	19144
@NP	the manufacturer 's	19144
@NP	Fluka	19177
@NP	Sigma	19184
@NP	5 min	19195
@NP	The tissue sections	19202
@NP	water followed by 1 % HCl in ethanol solution for 30 s.	19237
@NP	water	19237
@NP	1 % HCl in ethanol solution for 30 s.	19255
@NP	1 % HCl	19255
@NP	ethanol solution for 30 s.	19265
@NP	ethanol solution	19265
@NP	30 s.	19286
@NP	The sections	19292
@NP	water	19322
@NP	Eosin Y -LRB- Merck Millipore , Dramstadt , Germany -RRB- for 6 min	19351
@NP	Eosin Y -LRB- Merck Millipore , Dramstadt , Germany -RRB-	19351
@NP	Eosin Y	19351
@NP	Merck Millipore	19360
@NP	Dramstadt	19377
@NP	Germany	19388
@NP	6 min	19401
@NP	The sections	19408
@NP	DPX -LRB- Sigma -RRB-	19454
@NP	DPX	19454
@NP	Sigma	19459
@NP	Immunohistochemistry Spinal cord sections of GFP	19467
@NP	Immunohistochemistry	19467
@NP	Spinal cord sections of GFP	19488
@NP	Spinal cord sections	19488
@NP	GFP	19512
@NP	cell	19517
@NP	transplanted rats	19522
@NP	immunohistochemistry	19559
@NP	GFP -LRB- rabbit anti-GFP ; 1 : 200 ; Life Technologies -RRB- to localize	19588
@NP	rabbit anti-GFP	19593
@NP	1 : 200 ; Life Technologies	19610
@NP	1 : 200	19610
@NP	Life Technologies	19619
@NP	cells	19660
@NP	Other transverse sections	19667
@NP	primary antibody	19717
@NP	glial fibrillary acidic protein	19742
@NP	mouse anti-GFAP	19775
@NP	1 : 1000 ; Sigma-Aldrich	19792
@NP	1 : 1000	19792
@NP	Sigma-Aldrich	19802
@NP	astroglial reactivity and the glial scar formed around the lesion	19830
@NP	astroglial reactivity	19830
@NP	the glial scar formed around the lesion	19856
@NP	the glial scar	19856
@NP	the lesion	19885
@NP	Microglial/macrophage immunoreactivity	19897
@NP	antibody	19954
@NP	the	19971
@NP	calcium-binding adapter molecule 1	19983
@NP	calcium-binding adapter molecule	19983
@NP	1	20016
@NP	rabbit anti-Iba1 , 1	20019
@NP	rabbit anti-Iba1	20019
@NP	1	20037
@NP	1000 ; Wako	20041
@NP	1000	20041
@NP	Wako	20047
@NP	Neuronal survival in the ventral horns	20054
@NP	Neuronal survival	20054
@NP	the ventral horns	20075
@NP	transverse sections	20109
@NP	neuronal nuclei -LRB- mouse anti-NeuN ; 1 : 200 ; Millipore -RRB-	20145
@NP	neuronal nuclei	20145
@NP	mouse anti-NeuN	20162
@NP	1 : 200 ; Millipore	20179
@NP	1 : 200	20179
@NP	Millipore	20188
@NP	Tissue sections	20200
@NP	PBS	20234
@NP	0.3 % Triton and 5 % FBS	20256
@NP	0.3 % Triton	20256
@NP	5 % FBS	20272
@NP	24 h at 4 °C	20298
@NP	24 h	20298
@NP	4 °C	20306
@NP	the corresponding primary antibody	20316
@NP	PBS plus 0.3 % Triton and 2.5 % FBS	20362
@NP	PBS	20362
@NP	0.3 % Triton and 2.5 % FBS	20371
@NP	0.3 % Triton	20371
@NP	2.5 % FBS	20387
@NP	washes	20403
@NP	sections	20411
@NP	2 h at room temperature	20439
@NP	2 h	20439
@NP	room temperature	20446
@NP	secondary antibody	20468
@NP	donkey anti-rabbit AlexaFluor488 for GFP	20488
@NP	donkey anti-rabbit AlexaFluor488	20488
@NP	GFP	20525
@NP	donkey antimouse AlexaFluor594 for GFAP and NeuN	20530
@NP	donkey antimouse AlexaFluor594	20530
@NP	GFAP and NeuN	20565
@NP	donkey anti-rabbit AlexaFluor594 for Iba1 ; 1 : 200 ; Life Technologies	20580
@NP	donkey anti-rabbit AlexaFluor594	20580
@NP	Iba1 ; 1 : 200 ; Life Technologies	20617
@NP	Iba1	20617
@NP	1	20623
@NP	200	20627
@NP	Life Technologies	20632
@NP	Slides	20652
@NP	Citoseal 60 -LRB- Thermo Fisher Scientific , Madrid , Spain -RRB-	20692
@NP	Citoseal 60	20692
@NP	Thermo Fisher Scientific	20705
@NP	Madrid	20731
@NP	Spain	20739
@NP	all immunohistochemistry procedures	20750
@NP	we	20786
@NP	internal controls -LRB- for primary and secondary antibodies -RRB-	20798
@NP	internal controls	20798
@NP	primary and secondary antibodies	20821
@NP	non-specific staining	20865
@NP	All the antibodies used in this work	20888
@NP	All the antibodies	20888
@NP	this work	20915
@NP	no labeling	20944
@NP	any of the negative controls used	20972
@NP	any	20972
@NP	the negative controls used	20979
@NP	the negative controls	20979
@NP	Histological analysis Images	21007
@NP	a digital camera	21055
@NP	Olympus DP50	21073
@NP	the microscope -LRB- Olympus BX51 -RRB-	21099
@NP	the microscope	21099
@NP	Olympus BX51	21115
@NP	Analysis of the GFP + area	21130
@NP	Analysis	21130
@NP	the GFP + area	21142
@NP	the GFP	21142
@NP	area	21151
@NP	eight spinal cord sections	21176
@NP	360 µm between pairs	21217
@NP	360 µm	21217
@NP	pairs	21232
@NP	each animal	21242
@NP	Consecutive images of the SCI segment	21255
@NP	Consecutive images	21255
@NP	the SCI segment	21277
@NP	40 9	21307
@NP	the same setting	21317
@NP	the total section	21338
@NP	Photoshop software -LRB- Adobe Systems -RRB-	21374
@NP	Photoshop software	21374
@NP	Adobe Systems	21394
@NP	The microphotographs	21410
@NP	ImageJ software	21451
@NP	The GFP-labeled area in each section	21468
@NP	The GFP-labeled area	21468
@NP	each section	21492
@NP	a threshold for background correction	21533
@NP	a threshold	21533
@NP	background correction	21549
@NP	Analysis of spared tissue and injury size	21572
@NP	Analysis	21572
@NP	spared tissue and injury size	21584
@NP	19 transversal cord sections	21629
@NP	450 µm between pairs	21672
@NP	450 µm	21672
@NP	pairs	21687
@NP	each animal	21697
@NP	The transversal section images	21710
@NP	40 9	21755
@NP	the same setting	21765
@NP	The area of spared tissue , cavity and total spinal cord sections	21783
@NP	The area	21783
@NP	tissue , cavity and total spinal cord sections	21802
@NP	ImageJ software	21883
@NP	each section	21903
@NP	The volume of the graft , spared tissue , cavity and total SCI segment	21917
@NP	The volume	21917
@NP	the graft , spared tissue , cavity and total SCI segment	21931
@NP	the graft	21931
@NP	tissue , cavity and total SCI segment	21949
@NP	tissue	21949
@NP	cavity	21957
@NP	total SCI segment	21968
@NP	the Cavalieri 's estimator	22007
@NP	the Cavalieri 's	22007
@NP	morphometric volume -LRB- Rosen & Harry , 1990 -RRB-	22036
@NP	morphometric volume	22036
@NP	Rosen & Harry	22057
@NP	1990	22072
@NP	the effects of the cell grafts	22088
@NP	the effects	22088
@NP	the cell grafts	22103
@NP	glial reaction	22122
@NP	GFAPand Iba1-labeled areas	22138
@NP	three different levels	22182
@NP	3 mm rostral from the epicenter	22206
@NP	3 mm rostral	22206
@NP	the epicenter	22224
@NP	the section corresponding to the epicenter	22239
@NP	the section	22239
@NP	the epicenter	22268
@NP	3 mm caudal from the epicenter	22287
@NP	3 mm caudal	22287
@NP	the epicenter	22304
@NP	The analysis of the GFAP + area	22319
@NP	The analysis	22319
@NP	the GFAP + area	22335
@NP	the GFAP	22335
@NP	area	22345
@NP	both gray and white matter	22362
@NP	The labeled area	22390
@NP	the fraction with respect	22426
@NP	the fraction	22426
@NP	respect	22444
@NP	the total spinal cord section area	22455
@NP	Statistical and data analysis Quantitative data	22491
@NP	data analysis	22507
@NP	gait analysis , sensory tests and electrophysiology tests	22542
@NP	gait analysis	22542
@NP	sensory tests	22557
@NP	electrophysiology tests	22575
@NP	one-way ANOVA	22616
@NP	Data of graft volume	22631
@NP	Data	22631
@NP	graft volume	22639
@NP	two-way ANOVA	22672
@NP	Statistical analyses of the percentage of spared tissue and BBB score	22687
@NP	Statistical analyses	22687
@NP	the percentage of spared tissue and BBB score	22711
@NP	the percentage	22711
@NP	spared tissue and BBB score	22729
@NP	spared tissue	22729
@NP	BBB score	22747
@NP	twoway ANOVA of repeated measures	22775
@NP	twoway ANOVA	22775
@NP	repeated measures	22791
@NP	Bonferroni 's post hoc test for comparative pairs of groups	22810
@NP	Bonferroni 's post hoc test	22810
@NP	Bonferroni 's	22810
@NP	comparative pairs of groups	22841
@NP	comparative pairs	22841
@NP	groups	22862
@NP	all the comparisons	22882
@NP	a value of P	22903
@NP	a value	22903
@NP	P	22914
@NP	SEM	22965
@NP	Data from maximal treadmill speed	22987
@NP	Data	22987
@NP	maximal treadmill speed	22997
@NP	survival curves	23039
@NP	log-rank test	23058
@NP	Results Fig. 2 .	23074
@NP	Results	23074
@NP	Fig. 2	23082
@NP	Locomotion test	23090
@NP	The open field locomotion	23115
@NP	the injury using the BBB score in acute -LRB- A -RRB-	23168
@NP	the injury	23168
@NP	the BBB score	23185
@NP	A	23209
@NP	delayed transplantations -LRB- B -RRB-	23216
@NP	delayed transplantations	23216
@NP	B	23242
@NP	injury	23252
@NP	all the rats	23259
@NP	paralysis of the hindlimbs	23279
@NP	paralysis	23279
@NP	the hindlimbs	23292
@NP	partial recovery during the next 2 -- 3 weeks	23312
@NP	partial recovery during the next 2	23312
@NP	partial recovery	23312
@NP	the next 2	23336
@NP	3 weeks	23347
@NP	The dotted line	23356
@NP	a relevant point	23382
@NP	the BBB scale	23402
@NP	score of 9 points	23417
@NP	score	23417
@NP	9 points	23426
@NP	the capacity of the rats	23446
@NP	the capacity	23446
@NP	the rats	23462
@NP	body weight	23482
@NP	There	23495
@NP	slight improvements	23506
@NP	the delayed MSC and OEC transplants at 14 days compared with the VE group	23531
@NP	the delayed MSC and OEC transplants	23531
@NP	14 days compared with the VE group	23570
@NP	14 days	23570
@NP	the VE group	23592
@NP	-LRB- A -RRB- * P < 0.05 VE -- 0 dpo and MSC -- 0 dpo groups vs.	23606
@NP	-LRB- A -RRB-	23606
@NP	P <	23611
@NP	P	23611
@NP	<	23613
@NP	0.05 VE	23615
@NP	0 dpo and MSC -- 0 dpo groups vs.	23623
@NP	0 dpo and MSC	23623
@NP	0 dpo	23623
@NP	MSC	23633
@NP	0 dpo groups vs.	23637
@NP	0 dpo groups	23637
@NP	vs.	23650
@NP	OEC -- 0 dpo group .	23654
@NP	OEC	23654
@NP	0 dpo group	23658
@NP	-LRB- B -RRB- * P < 0.05 OEC -- 7 dpo and MSC -- 7 dpo groups vs.	23671
@NP	-LRB- B -RRB-	23671
@NP	P <	23676
@NP	P	23676
@NP	<	23678
@NP	0.05 OEC	23680
@NP	7 dpo and MSC -- 7 dpo groups vs.	23689
@NP	7 dpo and MSC	23689
@NP	7 dpo	23689
@NP	MSC	23699
@NP	7 dpo groups vs.	23703
@NP	7 dpo groups	23703
@NP	vs.	23716
@NP	VE -- 7 dpo group .	23720
@NP	VE	23720
@NP	7 dpo group	23723
@NP	The percentage of animals that were able to run at increasing treadmill speeds	23736
@NP	The percentage	23736
@NP	animals that were able to run at increasing treadmill speeds	23754
@NP	animals	23754
@NP	increasing treadmill speeds	23787
@NP	survival curves -LRB- C and D -RRB-	23831
@NP	survival curves	23831
@NP	C and D	23848
@NP	C	23848
@NP	D	23854
@NP	The P-value for each comparison	23858
@NP	The P-value	23858
@NP	each comparison	23874
@NP	the statistical significance of the log-rank test	23901
@NP	the statistical significance	23901
@NP	the log-rank test	23933
@NP	The gait performance during treadmill walking	23952
@NP	The gait performance	23952
@NP	treadmill walking	23980
@NP	the stance/swift ratio	24017
@NP	all the SCI animals	24050
@NP	similar disturbances -LRB- E and F , left panels -RRB-	24077
@NP	similar disturbances	24077
@NP	E and F ,	24099
@NP	E	24099
@NP	F	24105
@NP	panels	24113
@NP	The interlimb coordination , assessed using the RI ,	24122
@NP	The interlimb coordination	24122
@NP	the RI	24165
@NP	marked reduction	24180
@NP	all the injured rats -LRB- E and F , right panel -RRB-	24200
@NP	all the injured rats	24200
@NP	E and F , right panel	24222
@NP	E and F	24222
@NP	right panel	24231
@NP	-LRB- E and F -RRB- * P < 0.05 SCI groups vs. intact control rats	24245
@NP	-LRB- E and F -RRB-	24245
@NP	E	24246
@NP	F	24252
@NP	P <	24256
@NP	0.05	24260
@NP	SCI groups vs. intact control rats	24265
@NP	SCI groups	24265
@NP	intact control rats	24280
@NP	Fig. 2 .	24302
@NP	Fig.	24302
@NP	2	24307
@NP	Locomotion test	24310
@NP	The open field locomotion	24335
@NP	the injury using the BBB score in acute -LRB- A -RRB-	24388
@NP	the injury	24388
@NP	the BBB score	24405
@NP	A	24429
@NP	delayed transplantations -LRB- B -RRB-	24436
@NP	delayed transplantations	24436
@NP	B	24462
@NP	injury	24472
@NP	all the rats	24479
@NP	paralysis of the hindlimbs	24499
@NP	paralysis	24499
@NP	the hindlimbs	24512
@NP	partial recovery during the next 2 -- 3 weeks	24532
@NP	partial recovery during the next 2	24532
@NP	partial recovery	24532
@NP	the next 2	24556
@NP	3 weeks	24567
@NP	The dotted line	24576
@NP	a relevant point	24602
@NP	the BBB scale	24622
@NP	score of 9 points	24637
@NP	score	24637
@NP	9 points	24646
@NP	the capacity of the rats	24666
@NP	the capacity	24666
@NP	the rats	24682
@NP	body weight	24702
@NP	There	24715
@NP	slight improvements	24726
@NP	the delayed MSC and OEC transplants at 14 days compared with the VE group	24751
@NP	the delayed MSC and OEC transplants	24751
@NP	14 days compared with the VE group	24790
@NP	14 days	24790
@NP	the VE group	24812
@NP	-LRB- A -RRB- * P < 0.05 VE -- 0 dpo and MSC -- 0 dpo groups vs.	24826
@NP	-LRB- A -RRB-	24826
@NP	P <	24831
@NP	P	24831
@NP	<	24833
@NP	0.05 VE	24835
@NP	0 dpo and MSC -- 0 dpo groups vs.	24843
@NP	0 dpo and MSC	24843
@NP	0 dpo	24843
@NP	MSC	24853
@NP	0 dpo groups vs.	24857
@NP	0 dpo groups	24857
@NP	vs.	24870
@NP	OEC -- 0 dpo group .	24874
@NP	OEC	24874
@NP	0 dpo group	24878
@NP	-LRB- B -RRB- * P < 0.05 OEC -- 7 dpo and MSC -- 7 dpo groups vs.	24891
@NP	-LRB- B -RRB-	24891
@NP	P <	24896
@NP	P	24896
@NP	<	24898
@NP	0.05 OEC	24900
@NP	7 dpo and MSC -- 7 dpo groups vs.	24909
@NP	7 dpo and MSC	24909
@NP	7 dpo	24909
@NP	MSC	24919
@NP	7 dpo groups vs.	24923
@NP	7 dpo groups	24923
@NP	vs.	24936
@NP	VE -- 7 dpo group .	24940
@NP	VE	24940
@NP	7 dpo group	24943
@NP	The percentage of animals that were able to run at increasing treadmill speeds	24956
@NP	The percentage	24956
@NP	animals that were able to run at increasing treadmill speeds	24974
@NP	animals	24974
@NP	increasing treadmill speeds	25007
@NP	survival curves -LRB- C and D -RRB-	25051
@NP	survival curves	25051
@NP	C and D	25068
@NP	C	25068
@NP	D	25074
@NP	The P-value for each comparison	25078
@NP	The P-value	25078
@NP	each comparison	25094
@NP	the statistical significance of the log-rank test	25121
@NP	the statistical significance	25121
@NP	the log-rank test	25153
@NP	The gait performance during treadmill walking	25172
@NP	The gait performance	25172
@NP	treadmill walking	25200
@NP	the stance/swift ratio	25237
@NP	all the SCI animals	25270
@NP	similar disturbances -LRB- E and F , left panels -RRB-	25297
@NP	similar disturbances	25297
@NP	E and F ,	25319
@NP	E	25319
@NP	F	25325
@NP	panels	25333
@NP	The interlimb coordination , assessed using the RI ,	25342
@NP	The interlimb coordination	25342
@NP	the RI	25385
@NP	marked reduction	25400
@NP	all the injured rats -LRB- E and F , right panel -RRB-	25420
@NP	all the injured rats	25420
@NP	E and F , right panel	25442
@NP	E and F	25442
@NP	right panel	25451
@NP	-LRB- E and F -RRB- * P < 0.05 SCI groups vs. intact control rats	25465
@NP	-LRB- E and F -RRB-	25465
@NP	E	25466
@NP	F	25472
@NP	P <	25476
@NP	0.05	25480
@NP	SCI groups vs. intact control rats	25485
@NP	SCI groups	25485
@NP	intact control rats	25500
@NP	Fig. 3 .	25522
@NP	Fig.	25522
@NP	3	25527
@NP	Sensory test results .	25530
@NP	Sensory test	25530
@NP	results	25543
@NP	The responses	25552
@NP	noxious mechanical stimulus	25569
@NP	an electronic Von Frey device -LRB- A and B -RRB-	25612
@NP	an electronic Von Frey device	25612
@NP	A and B	25643
@NP	A	25643
@NP	B	25649
@NP	heat stimulus using the Plantar test -LRB- C and D -RRB-	25659
@NP	heat stimulus	25659
@NP	the Plantar test -LRB- C and D -RRB-	25679
@NP	the Plantar test	25679
@NP	C and D	25697
@NP	C	25697
@NP	D	25703
@NP	The threshold values	25707
@NP	percentages with respect	25747
@NP	percentages	25747
@NP	respect	25764
@NP	pre-operative values for each treatment group	25775
@NP	pre-operative values	25775
@NP	each treatment group	25800
@NP	the injury	25828
@NP	the thresholds of both sensory tests	25840
@NP	the thresholds	25840
@NP	both sensory tests	25858
@NP	all treatment conditions	25893
@NP	hypersensitivity in front	25930
@NP	hypersensitivity	25930
@NP	front	25950
@NP	noxious mechanical and thermal stimuli	25959
@NP	No differences	25999
@NP	acute or delayed transplant groups	26036
@NP	Fig. 4 .	26073
@NP	Fig.	26073
@NP	4	26078
@NP	Electrophysiological results	26081
@NP	Compound muscle action potential	26111
@NP	Compound muscle action	26111
@NP	plantar -LRB- PL -RRB- muscle before	26156
@NP	plantar -LRB- PL -RRB- muscle	26156
@NP	PL	26165
@NP	A , left panel	26184
@NP	A	26184
@NP	panel	26192
@NP	after -LRB- A , right panel -RRB- SCI	26203
@NP	after	26203
@NP	A , right panel	26210
@NP	A	26210
@NP	right panel	26213
@NP	SCI	26226
@NP	SCI	26237
@NP	no changes	26241
@NP	the amplitude of the M-wave	26269
@NP	the amplitude	26269
@NP	the M-wave	26286
@NP	the H-wave	26302
@NP	The increased H/M ratio after injury	26324
@NP	The increased H/M ratio	26324
@NP	injury	26354
@NP	hyper-reflexia in the spinal segments	26371
@NP	hyper-reflexia	26371
@NP	the spinal segments	26389
@NP	the damage	26415
@NP	The H/M ratio	26427
@NP	both acute and delayed MSC groups compared with OEC and VE groups -LRB- B -RRB-	26458
@NP	both acute and delayed MSC groups	26458
@NP	OEC and VE groups -LRB- B -RRB-	26506
@NP	OEC and VE groups	26506
@NP	B	26525
@NP	Representative	26529
@NP	recordings of MEPs of the tibialis	26544
@NP	recordings	26544
@NP	MEPs of the tibialis	26558
@NP	MEPs	26558
@NP	the tibialis	26566
@NP	anterior -LRB- TA -RRB- muscle before injury -LRB- C -RRB-	26579
@NP	anterior -LRB- TA -RRB- muscle	26579
@NP	TA	26589
@NP	injury -LRB- C -RRB-	26607
@NP	injury	26607
@NP	C	26615
@NP	injury and VE injection -LRB- D -RRB-	26625
@NP	injury and VE injection	26625
@NP	D	26650
@NP	injury and MSC injection -LRB- E -RRB-	26664
@NP	injury and MSC injection	26664
@NP	E	26690
@NP	intact rats	26697
@NP	MEPs	26709
@NP	a latency of about 6 ms -LRB- C , with arrow -RRB-	26718
@NP	a latency	26718
@NP	6 ms -LRB- C , with arrow -RRB-	26737
@NP	6 ms	26737
@NP	C , with arrow	26743
@NP	C	26743
@NP	arrow	26751
@NP	injury	26765
@NP	this early response	26772
@NP	a second slower response	26809
@NP	a latency of about 20 ms -LRB- D and E , black arrow -RRB-	26852
@NP	a latency	26852
@NP	about 20 ms -LRB- D and E , black arrow -RRB-	26865
@NP	about 20 ms	26865
@NP	D and E , black arrow	26878
@NP	D and E	26878
@NP	black arrow	26887
@NP	The amplitude	26901
@NP	the late MEP component	26918
@NP	the percentage	26945
@NP	animals that presented this response from TA	26963
@NP	animals	26963
@NP	this response	26986
@NP	TA	27005
@NP	gastrocnemius medialis -LRB- GM -RRB- muscles	27012
@NP	gastrocnemius medialis	27012
@NP	muscles	27040
@NP	the acute -LRB- F and H , respectively -RRB-	27068
@NP	the acute	27068
@NP	F and H , respectively	27079
@NP	F and H	27079
@NP	-LRB- G and I , respectively -RRB- treatments	27114
@NP	G and I , respectively	27115
@NP	G and I	27115
@NP	G	27115
@NP	I	27121
@NP	B and C	27151
@NP	B	27151
@NP	C	27157
@NP	P <	27161
@NP	P	27161
@NP	<	27163
@NP	0.05 injured groups vs. intact rats ;	27165
@NP	0.05 injured groups	27165
@NP	intact rats ;	27189
@NP	intact rats	27189
@NP	P <	27203
@NP	0.05 MSC group	27207
@NP	vs.	27222
@NP	OEC and VE groups .	27226
@NP	OEC and VE	27226
@NP	groups	27237
@NP	-LRB- A -RRB- Vertical bar = 2 mV ; horizontal bar = 2 ms.	27245
@NP	-LRB- A -RRB- Vertical bar = 2	27245
@NP	-LRB- A -RRB- Vertical bar	27245
@NP	A	27246
@NP	2	27264
@NP	mV ; horizontal bar = 2 ms.	27266
@NP	mV	27266
@NP	horizontal bar = 2 ms.	27270
@NP	2	27287
@NP	-LRB- C -RRB- Vertical bar = 10 mV ; horizontal bar = 5 ms.	27293
@NP	-LRB- C -RRB- Vertical bar = 10	27293
@NP	-LRB- C -RRB- Vertical bar	27293
@NP	C	27294
@NP	10	27312
@NP	mV ; horizontal bar = 5 ms.	27315
@NP	mV	27315
@NP	horizontal bar = 5 ms.	27319
@NP	5	27336
@NP	-LRB- D and E -RRB- Vertical bar = 50 lV ; horizontal bar = 5 ms.	27342
@NP	-LRB- D and E -RRB- Vertical bar = 50	27342
@NP	-LRB- D and E -RRB- Vertical bar	27342
@NP	D and E	27343
@NP	D	27343
@NP	E	27349
@NP	50	27367
@NP	lV ; horizontal bar = 5 ms.	27370
@NP	lV	27370
@NP	horizontal bar = 5 ms.	27374
@NP	5	27391
@NP	Fig. 5 .	27398
@NP	Fig.	27398
@NP	5	27403
@NP	Histological analysis .	27406
@NP	The analysis	27429
@NP	acute -LRB- A -RRB-	27467
@NP	acute	27467
@NP	A	27474
@NP	B	27490
@NP	transplantation	27493
@NP	SCI	27515
@NP	The amount of protected tissue	27520
@NP	The amount	27520
@NP	protected tissue	27534
@NP	the percentage	27570
@NP	tissue area	27595
@NP	respect	27612
@NP	the total area of the section	27623
@NP	the total area	27623
@NP	the section	27641
@NP	The measures	27654
@NP	hematoxylin-eosinstained transversal sections -LRB- A and B , bottom panel -RRB-	27680
@NP	hematoxylin-eosinstained transversal sections	27680
@NP	A and B , bottom panel	27727
@NP	A and B	27727
@NP	bottom panel	27736
@NP	the injured spinal cord segment at 6 weeks	27753
@NP	the injured spinal cord segment	27753
@NP	6 weeks	27788
@NP	SCI	27802
@NP	The comparison between acute and delayed treatment	27807
@NP	The comparison	27807
@NP	acute and delayed treatment	27830
@NP	the percentage	27879
@NP	spared volume -LRB- C -RRB- of vehicle -LRB- C , left panel -RRB-	27897
@NP	spared volume -LRB- C -RRB- of vehicle	27897
@NP	spared volume -LRB- C -RRB-	27897
@NP	spared volume	27897
@NP	C	27912
@NP	vehicle	27918
@NP	C , left panel	27927
@NP	C	27927
@NP	panel	27935
@NP	MSC -LRB- C , center panel -RRB- and OEC -LRB- C , right panel -RRB- groups	27943
@NP	MSC -LRB- C , center panel -RRB-	27943
@NP	MSC	27943
@NP	C , center panel	27948
@NP	C	27948
@NP	center panel	27951
@NP	OEC -LRB- C , right panel -RRB- groups	27969
@NP	OEC	27969
@NP	C , right panel	27974
@NP	C	27974
@NP	right panel	27977
@NP	groups	27990
@NP	The results	27998
@NP	tissue protection	28015
@NP	both MSC and OEC transplantation	28038
@NP	MSC	28043
@NP	OEC transplantation	28051
@NP	acute and delayed treatment	28079
@NP	differences between them	28120
@NP	differences	28120
@NP	them	28140
@NP	P	28147
@NP	< 0.05 MSC group vs.	28149
@NP	<	28149
@NP	0.05 MSC group vs.	28151
@NP	0.05 MSC group	28151
@NP	vs.	28166
@NP	VE group ; # P < 0.05 OEC group vs.	28170
@NP	VE group	28170
@NP	# P < 0.05 OEC group vs.	28180
@NP	# P	28180
@NP	group vs.	28194
@NP	group	28194
@NP	vs.	28200
@NP	VE group .	28204
@NP	VE	28204
@NP	group	28207
@NP	Fig. 6 .	28215
@NP	Fig.	28215
@NP	6	28220
@NP	Neuronal survival after SCI and cell transplantation .	28223
@NP	Neuronal survival	28223
@NP	SCI and cell transplantation	28247
@NP	SCI	28247
@NP	cell transplantation	28255
@NP	the end point	28280
@NP	immunohistochemistry against NeuN	28295
@NP	immunohistochemistry	28295
@NP	NeuN	28324
@NP	transversal spinal cord sections -LRB- A -RRB-	28346
@NP	transversal spinal cord sections	28346
@NP	A	28380
@NP	the ventral horn	28387
@NP	these sections -LRB- A , below dotted line -RRB-	28407
@NP	these sections	28407
@NP	A , below dotted line	28423
@NP	A	28423
@NP	dotted line	28432
@NP	the number of NeuN + cells -LRB- A , inset -RRB- was counted	28446
@NP	the number	28446
@NP	NeuN + cells -LRB- A , inset -RRB- was counted	28460
@NP	NeuN + cells -LRB- A , inset -RRB-	28460
@NP	NeuN + cells	28460
@NP	A , inset	28473
@NP	A	28473
@NP	Counts	28496
@NP	sections from 4 mm rostral	28516
@NP	sections	28516
@NP	4 mm rostral	28530
@NP	4 mm caudal	28546
@NP	the lesion epicenter	28561
@NP	the analysis	28587
@NP	acute -LRB- B -RRB-	28625
@NP	acute	28625
@NP	B	28632
@NP	C	28648
@NP	transplantation	28651
@NP	SCI	28673
@NP	The results	28678
@NP	a higher number of NeuN + cells in both MSC and OEC transplantation	28695
@NP	a higher number	28695
@NP	NeuN + cells in both MSC and OEC transplantation	28714
@NP	NeuN + cells	28714
@NP	both MSC and OEC transplantation	28729
@NP	MSC	28734
@NP	OEC transplantation	28742
@NP	both acute and delayed injection	28768
@NP	P	28804
@NP	< 0.01 and * P	28806
@NP	<	28806
@NP	0.01 and * P	28808
@NP	0.01 and	28808
@NP	P	28818
@NP	< 0.05 MSC group vs.	28820
@NP	<	28820
@NP	0.05 MSC group vs.	28822
@NP	0.05 MSC group	28822
@NP	vs.	28837
@NP	VE group ; & & & P < 0.001 , & & P < 0.01 and & P < 0.05 OEC group vs.	28841
@NP	VE group ; & & & P < 0.001 , & & P < 0.01 and & P <	28841
@NP	VE group ; & & & P < 0.001	28841
@NP	VE group	28841
@NP	&	28851
@NP	& & P <	28852
@NP	& P <	28853
@NP	& P	28853
@NP	<	28856
@NP	0.001	28858
@NP	& P < 0.01 and & P <	28866
@NP	& P < 0.01	28866
@NP	& P <	28866
@NP	& P	28866
@NP	0.01	28871
@NP	& P <	28880
@NP	& P	28880
@NP	<	28883
@NP	0.05 OEC group vs.	28885
@NP	0.05 OEC group	28885
@NP	vs.	28900
@NP	VE group .	28904
@NP	VE	28904
@NP	group	28907
@NP	Scale bar : 400 µm -LRB- A -RRB- ; 50 µm -LRB- A inset -RRB- .	28914
@NP	Scale bar : 400 µm -LRB- A -RRB-	28914
@NP	Scale bar	28914
@NP	400 µm -LRB- A -RRB-	28925
@NP	A	28933
@NP	50 µm -LRB- A inset -RRB-	28937
@NP	50 µm	28937
@NP	A inset	28944
@NP	A	28944
@NP	Fig. 7 .	28955
@NP	Fig.	28955
@NP	7	28960
@NP	Astroglial reactivity after SCI and cell transplantation .	28963
@NP	Astroglial reactivity	28963
@NP	SCI and cell transplantation	28991
@NP	SCI	28991
@NP	cell transplantation	28999
@NP	the end point	29024
@NP	immunohistochemistry against GFAP	29039
@NP	immunohistochemistry	29039
@NP	GFAP	29068
@NP	the amount of astrocytes in transversal spinal cord sections -LRB- A -RRB-	29094
@NP	the amount	29094
@NP	astrocytes in transversal spinal cord sections -LRB- A -RRB-	29108
@NP	astrocytes	29108
@NP	transversal spinal cord sections -LRB- A -RRB-	29122
@NP	transversal spinal cord sections	29122
@NP	A	29156
@NP	The percentage of GFAP + immunostained area	29160
@NP	The percentage	29160
@NP	GFAP + immunostained area	29178
@NP	GFAP	29178
@NP	immunostained area	29184
@NP	both gray -LRB- A1 -RRB- and white -LRB- A2 and A3 -RRB- matter	29221
@NP	gray -LRB- A1 -RRB-	29226
@NP	white -LRB- A2 and A3 -RRB- matter	29240
@NP	A2 and A3	29247
@NP	A2	29247
@NP	A3	29254
@NP	spinal cord sections	29269
@NP	3 mm rostral and 3 mm caudal	29307
@NP	3 mm rostral	29307
@NP	3 mm caudal	29324
@NP	the epicenter	29339
@NP	the epicenter	29366
@NP	The analysis	29381
@NP	acute -LRB- B -RRB-	29419
@NP	acute	29419
@NP	B	29426
@NP	C	29442
@NP	transplantation	29445
@NP	SCI	29467
@NP	both -LRB- B -RRB- and -LRB- C -RRB-	29475
@NP	both -LRB- B -RRB-	29475
@NP	-LRB- C -RRB-	29488
@NP	the left graphs	29493
@NP	the white mater and the right graphs the gray matter measurements	29519
@NP	the white mater	29519
@NP	the right graphs the gray matter measurements	29539
@NP	the right graphs	29539
@NP	the gray matter measurements	29556
@NP	The results	29586
@NP	an increase of GFAP	29603
@NP	an increase	29603
@NP	GFAP	29618
@NP	positive area	29624
@NP	the epicenter compared with both rostral and caudal sections	29641
@NP	the epicenter	29641
@NP	both rostral and caudal sections	29669
@NP	rostral	29674
@NP	caudal sections	29686
@NP	any difference between groups	29715
@NP	any difference	29715
@NP	groups	29738
@NP	Scale bar : 400 µm -LRB- A -RRB- ; 50 µm -LRB- A1 , A2 and A3 -RRB- .	29746
@NP	Scale bar	29746
@NP	400 µm -LRB- A -RRB- ; 50 µm -LRB- A1 , A2 and A3 -RRB-	29757
@NP	400 µm -LRB- A -RRB-	29757
@NP	A	29765
@NP	50 µm -LRB- A1 , A2 and A3 -RRB-	29769
@NP	A1 , A2 and A3	29776
@NP	A1	29776
@NP	A2 and A3	29780
@NP	C , section 3 mm caudal to the epicenter	29792
@NP	C	29792
@NP	section 3 mm caudal to the epicenter	29795
@NP	section 3 mm caudal	29795
@NP	the epicenter	29818
@NP	E , epicenter section	29833
@NP	E	29833
@NP	epicenter section	29836
@NP	R , section 3 mm rostral to the epicenter	29855
@NP	R	29855
@NP	section 3 mm rostral to the epicenter	29858
@NP	section 3 mm rostral	29858
@NP	the epicenter	29882
@NP	Fig. 8 .	29898
@NP	Fig.	29898
@NP	8	29903
@NP	Microglial/macrophages	29906
@NP	SCI and cell transplantation	29946
@NP	SCI	29946
@NP	cell transplantation	29954
@NP	the end point	29979
@NP	immunohistochemistry against Iba1	29994
@NP	immunohistochemistry	29994
@NP	Iba1	30023
@NP	the amount	30049
@NP	microglial/macrophages reactivity	30063
@NP	transversal spinal cord sections -LRB- A -RRB-	30100
@NP	transversal spinal cord sections	30100
@NP	A	30134
@NP	The percentage of Iba1 + immunostained area	30138
@NP	The percentage	30138
@NP	Iba1 + immunostained area	30156
@NP	Iba1	30156
@NP	immunostained area	30162
@NP	the white mater -LRB- A1 and A2 -RRB-	30197
@NP	the white mater	30197
@NP	A1 and A2	30214
@NP	A1	30214
@NP	A2	30221
@NP	The analysis	30226
@NP	spinal cord sections	30256
@NP	3 mm rostral and 3 mm caudal	30294
@NP	3 mm rostral	30294
@NP	3 mm caudal	30311
@NP	the epicenter	30326
@NP	the epicenter	30353
@NP	The analysis	30368
@NP	acute -LRB- B -RRB-	30406
@NP	acute	30406
@NP	B	30413
@NP	C	30429
@NP	transplantation	30432
@NP	SCI	30454
@NP	The results	30459
@NP	a reduction in Iba1-immunostained area in caudal sections	30480
@NP	a reduction	30480
@NP	Iba1-immunostained area in caudal sections	30495
@NP	Iba1-immunostained area	30495
@NP	caudal sections	30522
@NP	MSC or OEC acute transplantation	30544
@NP	MSC	30544
@NP	OEC acute transplantation	30551
@NP	the case of delayed cell injection	30581
@NP	the case	30581
@NP	delayed cell injection	30593
@NP	a reduction in Iba1-immunostained area	30617
@NP	a reduction	30617
@NP	Iba1-immunostained area	30632
@NP	both rostral and caudal sections	30672
@NP	rostral	30677
@NP	caudal sections	30689
@NP	MSC or OEC transplantation	30711
@NP	There	30739
@NP	no significant changes at the epicenter in any experimental condition	30750
@NP	no significant changes	30750
@NP	the epicenter in any experimental condition	30776
@NP	the epicenter	30776
@NP	any experimental condition	30793
@NP	Scale bar : 400 µm -LRB- A -RRB- ; 50 µm -LRB- A1 , A2 -RRB- .	30821
@NP	Scale bar	30821
@NP	400 µm -LRB- A -RRB- ; 50 µm -LRB- A1 , A2 -RRB-	30832
@NP	400 µm -LRB- A -RRB-	30832
@NP	A	30840
@NP	50 µm -LRB- A1 , A2 -RRB-	30844
@NP	A1 , A2	30851
@NP	A1	30851
@NP	A2	30855
@NP	C , section 3 mm caudal to epicenter	30860
@NP	C	30860
@NP	section 3 mm caudal to epicenter	30863
@NP	section 3 mm caudal	30863
@NP	epicenter	30886
@NP	E , epicenter section	30897
@NP	E	30897
@NP	epicenter section	30900
@NP	R , section 3 mm rostral to epicenter	30919
@NP	R	30919
@NP	section 3 mm rostral to epicenter	30922
@NP	section 3 mm rostral	30922
@NP	epicenter	30946
@NP	P < 0.05 MSC and OEC groups vs.	30958
@NP	P	30958
@NP	< 0.05 MSC and OEC groups vs.	30960
@NP	<	30960
@NP	0.05 MSC and OEC groups vs.	30962
@NP	0.05 MSC	30962
@NP	OEC groups	30975
@NP	VE group .	30990
@NP	VE	30990
@NP	group	30993
@NP	Graft survival	31001
@NP	the spinal cord One week after transplantation , the GFP + cells	31021
@NP	the spinal cord	31021
@NP	One week	31037
@NP	transplantation , the GFP + cells	31052
@NP	transplantation	31052
@NP	the GFP	31069
@NP	cells	31078
@NP	the epicenter of the injury	31107
@NP	the epicenter	31107
@NP	the injury	31124
@NP	the rostral and caudal injection sites -LRB- Fig. 1A -RRB-	31145
@NP	the rostral	31145
@NP	caudal injection sites -LRB- Fig. 1A -RRB-	31161
@NP	caudal injection sites	31161
@NP	Fig. 1A	31185
@NP	A strong reduction of the amount of GFP	31195
@NP	A strong reduction	31195
@NP	the amount of GFP	31217
@NP	the amount	31217
@NP	GFP	31231
@NP	2 weeks	31251
@NP	3 weeks	31274
@NP	all groups -LRB- Fig. 1B -- D -RRB-	31300
@NP	all groups	31300
@NP	Fig. 1B -- D	31312
@NP	Fig. 1B	31312
@NP	D	31320
@NP	a significant main effect of time	31330
@NP	a significant main effect	31330
@NP	time	31359
@NP	two-way ANOVA	31377
@NP	MSC grafting -LRB- F2 ,12 = 106.81 , P < 0.0001 ; Fig. 1E -RRB-	31397
@NP	MSC grafting	31397
@NP	F2 ,12 = 106.81 , P	31411
@NP	F2 ,12	31411
@NP	106.81 , P	31419
@NP	106.81	31419
@NP	P	31427
@NP	0.0001 ; Fig. 1E	31431
@NP	0.0001	31431
@NP	Fig. 1E	31439
@NP	OEC grafting -LRB- F2 ,12 = 48.29 , P < 0.0001 ; Fig. 1F -RRB-	31452
@NP	OEC grafting	31452
@NP	F2 ,12 = 48.29 , P < 0.0001 ; Fig. 1F	31466
@NP	F2 ,12 = 48.29	31466
@NP	F2 ,12	31466
@NP	48.29	31474
@NP	P < 0.0001 ; Fig. 1F	31481
@NP	P < 0.0001	31481
@NP	P	31481
@NP	0.0001	31485
@NP	Fig. 1F	31493
@NP	Fig.	31493
@NP	1F	31498
@NP	the GFP + volume	31509
@NP	the GFP	31509
@NP	volume	31518
@NP	delayed gMSC grafting at 1 week after injection	31553
@NP	delayed gMSC	31553
@NP	1 week after injection	31578
@NP	1 week	31578
@NP	injection	31591
@NP	the decrease from 7 to 14 days after injection	31602
@NP	the decrease	31602
@NP	7 to 14 days after injection	31620
@NP	7 to 14 days	31620
@NP	injection	31639
@NP	delayed gMSC transplants	31686
@NP	two-way ANOVA interaction F2 ,12 = 24.44 , P < 0.0001 ; Fig. 1E	31712
@NP	two-way ANOVA interaction	31712
@NP	F2 ,12	31738
@NP	24.44 , P < 0.0001 ; Fig. 1E	31746
@NP	24.44	31746
@NP	P < 0.0001 ; Fig. 1E	31753
@NP	P < 0.0001	31753
@NP	P	31753
@NP	0.0001	31757
@NP	Fig. 1E	31765
@NP	Fig.	31765
@NP	1E	31770
@NP	A similar result	31775
@NP	14 days	31808
@NP	gOEC transplantation	31822
@NP	lower GFP	31849
@NP	volume	31859
@NP	delayed transplants -LRB- Fig. 1F -RRB-	31896
@NP	delayed transplants	31896
@NP	Fig. 1F	31917
@NP	statistical significance	31939
@NP	the gMSC	31975
@NP	gOEC after acute -LRB- Fig. 1G -RRB- or delayed -LRB- Fig. 1H -RRB- treatment	31988
@NP	acute -LRB- Fig. 1G -RRB-	31999
@NP	acute	31999
@NP	Fig. 1G	32006
@NP	Fig. 1H	32027
@NP	no significant differences	32047
@NP	a similar GFP signal reduction	32090
@NP	both types of cells	32140
@NP	both types	32140
@NP	cells	32154
@NP	These observations	32161
@NP	the survival of grafted cells	32194
@NP	the survival	32194
@NP	grafted cells	32210
@NP	time	32248
@NP	2 weeks	32276
@NP	the transplant	32290
@NP	acute transplantation of the cells	32320
@NP	acute transplantation	32320
@NP	the cells	32345
@NP	their survival	32369
@NP	delayed injection	32389
@NP	Locomotor function	32408
@NP	The BBB open field locomotion score	32427
@NP	the gross voluntary locomotion activity	32480
@NP	SCI	32526
@NP	all the injured groups	32534
@NP	there	32557
@NP	paralysis	32567
@NP	the hindlimbs -LRB- 0 score -RRB-	32580
@NP	the hindlimbs	32580
@NP	0 score	32595
@NP	3 days post-injury , followed by recovery during the next 2 weeks	32607
@NP	3 days post-injury	32607
@NP	recovery	32639
@NP	the next 2 weeks	32655
@NP	Fig. 2A and B	32673
@NP	Fig. 2A	32673
@NP	B	32685
@NP	The animals	32689
@NP	a plateau	32710
@NP	significant recovery	32728
@NP	the last 3 weeks of follow-up	32756
@NP	the last 3 weeks	32756
@NP	follow-up	32776
@NP	a BBB score of about 10 -- 11 points	32791
@NP	a BBB score of about 10	32791
@NP	a BBB score	32791
@NP	10	32812
@NP	11 points	32815
@NP	the early phase	32833
@NP	there	32850
@NP	only a few differences between groups	32861
@NP	only a few differences	32861
@NP	groups	32892
@NP	the acute MSC transplant and the vehicle groups	32900
@NP	the acute MSC transplant	32900
@NP	the vehicle groups	32929
@NP	higher BBB score	32955
@NP	the OEC transplant group	32977
@NP	7 days -LRB- VE -- 0 dpo vs.	33005
@NP	7 days	33005
@NP	VE	33013
@NP	0 dpo	33016
@NP	0	33016
@NP	dpo	33018
@NP	vs.	33022
@NP	OEC -- 7 dpo : Bonferroni t = 2.95 , P < 0.05 ; MSC -- 0 dpo vs.	33026
@NP	OEC	33026
@NP	7 dpo : Bonferroni t = 2.95 , P < 0.05 ;	33030
@NP	7 dpo	33030
@NP	Bonferroni t = 2.95 , P < 0.05	33037
@NP	Bonferroni t = 2.95 , P <	33037
@NP	Bonferroni t	33037
@NP	= 2.95 , P <	33050
@NP	2.95 , P	33052
@NP	2.95	33052
@NP	P	33058
@NP	0.05	33062
@NP	MSC	33068
@NP	0 dpo	33072
@NP	vs.	33078
@NP	OEC -- 7 dpo : Bonferroni t = 2.92 , P < 0.01 ; Fig. 2A -RRB- ,	33082
@NP	OEC	33082
@NP	7 dpo : Bonferroni t = 2.92 , P < 0.01 ; Fig. 2A -RRB- ,	33087
@NP	7 dpo	33087
@NP	Bonferroni t = 2.92 , P < 0.01 ; Fig. 2A -RRB- ,	33094
@NP	Bonferroni t	33094
@NP	= 2.92 , P < 0.01 ; Fig. 2A -RRB- ,	33107
@NP	= 2.92	33107
@NP	P < 0.01 ; Fig. 2A -RRB-	33115
@NP	P	33115
@NP	0.01 ; Fig. 2A	33119
@NP	0.01	33119
@NP	Fig. 2A	33125
@NP	both subacute cell transplants	33143
@NP	higher scores than vehicle	33178
@NP	higher scores	33178
@NP	vehicle	33197
@NP	14 days -LRB- VE -- 7 dpo vs.	33208
@NP	14 days	33208
@NP	VE	33217
@NP	7 dpo	33220
@NP	7	33220
@NP	dpo	33222
@NP	vs.	33226
@NP	MSC -- 7 dpo : Bonferroni t = 3.27 , P < 0.05 ; VE -- 7 dpo vs.	33230
@NP	MSC	33230
@NP	7 dpo : Bonferroni t = 3.27 , P < 0.05 ;	33234
@NP	7 dpo	33234
@NP	Bonferroni t = 3.27 , P < 0.05	33241
@NP	Bonferroni t = 3.27 , P <	33241
@NP	Bonferroni t	33241
@NP	= 3.27 , P <	33254
@NP	3.27 , P	33256
@NP	3.27	33256
@NP	P	33262
@NP	0.05	33266
@NP	VE	33272
@NP	7 dpo	33276
@NP	vs.	33282
@NP	OEC -- 7 dpo : Bonferroni t = 3.29 , P < 0.01 ; Fig. 2B -RRB- .	33286
@NP	OEC	33286
@NP	7 dpo	33290
@NP	Bonferroni t = 3.29	33297
@NP	Bonferroni t	33297
@NP	3.29	33312
@NP	P < 0.01 ; Fig. 2B -RRB-	33318
@NP	P	33318
@NP	0.01 ; Fig. 2B	33322
@NP	0.01	33322
@NP	Fig. 2B	33328
@NP	No significant differences	33338
@NP	the acute	33384
@NP	the subacute	33398
@NP	groups	33420
@NP	the plateau phase	33434
@NP	Digigait Non-injured animals	33453
@NP	maximal treadmill speed about 80 cm/s	33502
@NP	maximal treadmill speed	33502
@NP	80 cm/s	33532
@NP	all injured groups	33544
@NP	the rats	33564
@NP	their weight	33583
@NP	stance	33599
@NP	all	33610
@NP	5 cm/s treadmill speed	33634
@NP	acute treatment	33661
@NP	significantly more rats of the MSC group	33677
@NP	significantly more rats	33677
@NP	the MSC group	33704
@NP	higher speeds	33750
@NP	the groups OEC	33772
@NP	VE	33791
@NP	log-rank test , P-value 0.008 and 0.04 , respectively	33795
@NP	log-rank test , P-value 0.008 and 0.04	33795
@NP	log-rank test	33795
@NP	0.008 and 0.04	33818
@NP	a higher median speed -LRB- MSC --	33854
@NP	a higher median speed	33854
@NP	MSC	33877
@NP	0 dpo	33881
@NP	37.5 cm/s	33888
@NP	OEC	33899
@NP	0 dpo	33903
@NP	30 cm/s	33910
@NP	VE	33919
@NP	0 dpo	33923
@NP	20 cm/s	33930
@NP	Fig. 2C	33939
@NP	No statistical differences	33949
@NP	OEC and VE acute groups	33998
@NP	subacute treatment	34028
@NP	no significant differences	34048
@NP	the three groups	34094
@NP	the MSC transplant	34121
@NP	the other two groups	34171
@NP	The analysis of the gait parameters and interlimb coordination	34193
@NP	The analysis	34193
@NP	the gait parameters and interlimb coordination	34209
@NP	20 cm/s treadmill speed -LRB- Redondo-Castro et al. , 2013 -RRB-	34274
@NP	20 cm/s treadmill speed	34274
@NP	Redondo-Castro	34299
@NP	et al. , 2013	34314
@NP	et al.	34314
@NP	2013	34322
@NP	SCI	34335
@NP	the animals	34340
@NP	the forelimb step	34362
@NP	the hindlimb step number	34392
@NP	a consequence	34421
@NP	the stance and swing time for each step	34436
@NP	the stance and swing time	34436
@NP	each step	34466
@NP	forelimbs	34489
@NP	the stance time	34506
@NP	hindlimbs	34535
@NP	These changes	34546
@NP	the stance/swing ratio	34578
@NP	both fore - and hindlimbs	34620
@NP	both fore	34620
@NP	hindlimbs	34635
@NP	the injury in comparison	34651
@NP	the injury	34651
@NP	comparison	34665
@NP	intact rats	34681
@NP	There	34694
@NP	no significant differences	34705
@NP	treatment groups	34740
@NP	the gait parameters	34760
@NP	two-way ANOVA : F3 ,50 = 8.39 , P = 0.0001 ; Fig. 2E ,	34781
@NP	two-way ANOVA	34781
@NP	F3 ,50 = 8.39	34796
@NP	F3 ,50	34796
@NP	8.39	34804
@NP	P = 0.0001 ; Fig. 2E	34810
@NP	P = 0.0001	34810
@NP	P	34810
@NP	0.0001	34814
@NP	Fig. 2E	34822
@NP	panel ; F3 ,42 = 12.22 , P < 0.0001 ; Fig. 2F ,	34836
@NP	panel ; F3 ,42 = 12.22	34836
@NP	panel	34836
@NP	F3 ,42 = 12.22	34843
@NP	F3 ,42	34843
@NP	12.22	34851
@NP	P < 0.0001 ; Fig. 2F	34858
@NP	P	34858
@NP	0.0001 ; Fig. 2F	34862
@NP	0.0001	34862
@NP	Fig. 2F	34870
@NP	panel	34884
@NP	the other hand	34895
@NP	the RI for alternating step pattern , used as a measure of global coordination ,	34911
@NP	the RI	34911
@NP	step pattern	34934
@NP	a measure of global coordination	34956
@NP	a measure	34956
@NP	global coordination	34969
@NP	all the groups	35014
@NP	injury	35035
@NP	one-way	35043
@NP	ANOVA : F = 124.1 ,	35051
@NP	ANOVA	35051
@NP	F = 124.1	35058
@NP	F	35058
@NP	124.1	35062
@NP	P < 0.0001 ; Fig. 2E , right panel ; F = 121.9	35069
@NP	P < 0.0001	35069
@NP	P	35069
@NP	0.0001	35073
@NP	Fig. 2E , right panel	35081
@NP	Fig. 2E	35081
@NP	right panel	35090
@NP	F = 121.9	35103
@NP	F	35103
@NP	121.9	35107
@NP	P < 0.0001	35114
@NP	P	35114
@NP	0.0001	35118
@NP	Fig. 2F , right panel	35126
@NP	Fig. 2F	35126
@NP	right panel	35135
@NP	Sensory function	35149
@NP	The sensory responses to mechanical and heat noxious stimuli	35166
@NP	The sensory responses	35166
@NP	mechanical and heat noxious stimuli	35191
@NP	mechanical	35191
@NP	heat noxious stimuli	35206
@NP	the end of the follow-up with Von Frey and Planter algesimetry tests	35245
@NP	the end	35245
@NP	the follow-up with Von Frey and Planter algesimetry tests	35256
@NP	the follow-up	35256
@NP	Von Frey and Planter algesimetry tests	35275
@NP	The withdrawal thresholds	35329
@NP	the pre-operative values	35370
@NP	each animal	35399
@NP	a decrease	35419
@NP	tests	35438
@NP	the spinal cord contusion	35450
@NP	hyperalgesia -LRB- Fig. 3 -RRB-	35491
@NP	hyperalgesia	35491
@NP	Fig. 3	35505
@NP	There	35514
@NP	no significant changes between any of the acute or subacute treatment groups	35525
@NP	no significant changes	35525
@NP	any of the acute or subacute treatment groups	35556
@NP	any	35556
@NP	the acute or subacute treatment groups	35563
@NP	Electrophysiology	35603
@NP	Spinal reflexes	35629
@NP	Electrical stimulation	35645
@NP	the sciatic nerve evoked in all the animals two consecutive muscle responses	35671
@NP	the sciatic nerve	35671
@NP	all the animals two consecutive muscle responses	35699
@NP	all the animals	35699
@NP	two consecutive muscle responses	35715
@NP	the M	35749
@NP	the H-waves	35760
@NP	the end of the follow-up , 6 weeks after injury	35776
@NP	the end	35776
@NP	the follow-up , 6 weeks after injury	35787
@NP	the follow-up	35787
@NP	6 weeks after injury	35802
@NP	6 weeks	35802
@NP	injury	35816
@NP	neither the amplitude nor the latency of the M-waves	35824
@NP	the amplitude	35832
@NP	the latency of the M-waves	35850
@NP	the latency	35850
@NP	the M-waves	35865
@NP	the SCI rats	35906
@NP	contrast	35923
@NP	the H-wave amplitude	35933
@NP	injury -LRB- Fig. 4A -RRB-	35970
@NP	injury	35970
@NP	Fig. 4A	35978
@NP	the H/M amplitude ratio	35994
@NP	injury in all animals with respect	36047
@NP	injury	36047
@NP	all animals with respect	36057
@NP	all animals	36057
@NP	respect	36074
@NP	pre-operative values	36085
@NP	hyper-reflexia	36118
@NP	one-way	36134
@NP	ANOVA : F = 27.52 , P < 0.0001 ; Fig. 4B ,	36142
@NP	ANOVA : F = 27.52	36142
@NP	ANOVA	36142
@NP	F = 27.52	36149
@NP	F	36149
@NP	27.52	36153
@NP	P < 0.0001 ; Fig. 4B	36160
@NP	P	36160
@NP	0.0001 ; Fig. 4B	36164
@NP	0.0001	36164
@NP	Fig. 4B	36172
@NP	panel ; F = 55.15 , P < 0.0001 ; Fig. 4B , right panel	36186
@NP	panel ; F = 55.15	36186
@NP	panel	36186
@NP	F = 55.15	36193
@NP	F	36193
@NP	55.15	36197
@NP	P < 0.0001 ; Fig. 4B , right panel	36204
@NP	P < 0.0001	36204
@NP	P	36204
@NP	0.0001	36208
@NP	Fig. 4B , right panel	36216
@NP	Fig. 4B	36216
@NP	right panel	36225
@NP	This increase	36239
@NP	acute MSC	36281
@NP	OEC and VE treated groups -LRB- MSC -- 0 dpo vs.	36299
@NP	OEC	36299
@NP	VE treated groups -LRB- MSC -- 0 dpo vs.	36307
@NP	VE treated groups	36307
@NP	MSC -- 0 dpo vs.	36326
@NP	MSC	36326
@NP	0 dpo vs.	36330
@NP	0 dpo	36330
@NP	vs.	36336
@NP	VE -- 0 dpo : Bonferroni t = 2.99 , P < 0.05 ; MSC -- 0 dpo vs.	36340
@NP	VE	36340
@NP	0 dpo : Bonferroni t = 2.99 , P < 0.05 ;	36343
@NP	0 dpo	36343
@NP	Bonferroni t = 2.99 , P < 0.05	36350
@NP	Bonferroni t = 2.99 , P <	36350
@NP	Bonferroni t	36350
@NP	= 2.99 , P <	36363
@NP	2.99 , P	36365
@NP	2.99	36365
@NP	P	36371
@NP	0.05	36375
@NP	MSC	36381
@NP	0 dpo	36385
@NP	vs.	36391
@NP	OEC	36395
@NP	0 dpo	36399
@NP	Bonferroni t = 3.34 , P < 0.01 -RRB-	36406
@NP	Bonferroni t = 3.34	36406
@NP	Bonferroni t	36406
@NP	3.34	36421
@NP	P < 0.01	36427
@NP	P <	36427
@NP	P	36427
@NP	0.01	36431
@NP	in subacute MSC than VE groups -LRB- MSC -- 7 dpo vs.	36442
@NP	subacute MSC	36445
@NP	VE groups -LRB- MSC -- 7 dpo vs.	36463
@NP	VE groups	36463
@NP	MSC	36474
@NP	7 dpo	36479
@NP	7	36479
@NP	dpo	36481
@NP	vs.	36485
@NP	VE -- 7 dpo : Bonferroni t = 3.33 , P < 0.05 ; Fig. 4B -RRB- .	36489
@NP	VE	36489
@NP	7 dpo	36492
@NP	Bonferroni t = 3.33	36499
@NP	Bonferroni t	36499
@NP	3.33	36514
@NP	P < 0.05 ; Fig. 4B -RRB-	36520
@NP	P	36520
@NP	0.05 ; Fig. 4B	36524
@NP	0.05	36524
@NP	Fig. 4B	36530
@NP	Motor-evoked potentials	36540
@NP	the injury , MEPs	36573
@NP	the injury	36573
@NP	MEPs	36585
@NP	a single wave	36607
@NP	a mean latency of ~ 8	36627
@NP	a mean latency	36627
@NP	~ 8	36645
@NP	~ 6 and ~ 6 ms	36649
@NP	amplitude of ~ 0.22 , ~ 14 and ~ 8.1 mV ,	36672
@NP	amplitude	36672
@NP	~ 0.22 , ~ 14 and ~ 8.1 mV ,	36685
@NP	~ 0.22	36685
@NP	~ 14 and ~ 8.1 mV	36692
@NP	PL , TA and GM muscles , respectively -LRB- Fig. 4C -RRB-	36712
@NP	PL , TA and GM muscles , respectively	36712
@NP	PL	36712
@NP	TA and GM muscles	36716
@NP	Fig. 4C	36749
@NP	all the injured rats	36762
@NP	the MEP	36783
@NP	the follow-up	36812
@NP	only a few animals	36831
@NP	a very small response -LRB- < 50 lV -RRB-	36860
@NP	a very small response	36860
@NP	< 50 lV	36883
@NP	<	36883
@NP	50 lV	36885
@NP	the normal latency	36895
@NP	42 dpo -LRB- Fig. 4D -RRB-	36917
@NP	42 dpo	36917
@NP	Fig. 4D	36925
@NP	A late MEP response -LRB- latency ~ 20 ms -RRB- and polyphasic	36935
@NP	A late MEP response -LRB- latency ~ 20 ms -RRB-	36935
@NP	A late MEP response	36935
@NP	latency ~ 20 ms	36956
@NP	latency ~	36956
@NP	20 ms	36965
@NP	polyphasic	36976
@NP	injury	37002
@NP	TA and GM muscles	37012
@NP	Fig. 4D and E	37031
@NP	Fig. 4D	37031
@NP	E	37043
@NP	the acute treatment groups	37050
@NP	the mean amplitude of this second component	37078
@NP	the mean amplitude	37078
@NP	this second component	37100
@NP	MSC	37136
@NP	OEC and VE groups -LRB- MSC -- 0 dpo vs.	37145
@NP	OEC and VE groups	37145
@NP	MSC	37164
@NP	0 dpo	37168
@NP	0	37168
@NP	dpo	37170
@NP	vs.	37174
@NP	VE -- 0 dpo : Bonferroni t = 2.85 , P < 0.05 ; MSC -- 0 dpo vs.	37178
@NP	VE	37178
@NP	0 dpo : Bonferroni t = 2.85 , P < 0.05 ;	37181
@NP	0 dpo	37181
@NP	Bonferroni t = 2.85 , P < 0.05	37188
@NP	Bonferroni t = 2.85	37188
@NP	Bonferroni t	37188
@NP	= 2.85	37201
@NP	P < 0.05	37209
@NP	P <	37209
@NP	P	37209
@NP	0.05	37213
@NP	MSC	37219
@NP	0 dpo	37223
@NP	vs.	37229
@NP	OEC -- 0 dpo : Bonferroni t = 2.94 , P < 0.05 ; Fig. 4F -RRB- .	37233
@NP	OEC	37233
@NP	0 dpo	37237
@NP	Bonferroni t = 2.94	37244
@NP	Bonferroni t	37244
@NP	= 2.94	37257
@NP	P < 0.05 ; Fig. 4F -RRB-	37265
@NP	P	37265
@NP	0.05 ; Fig. 4F	37269
@NP	0.05	37269
@NP	Fig. 4F	37275
@NP	the other hand	37288
@NP	the mean amplitude	37313
@NP	the delayed VE group compared with both MSC	37346
@NP	the delayed VE group	37346
@NP	both MSC	37381
@NP	7 dpo and OEC	37390
@NP	7 dpo	37390
@NP	OEC	37400
@NP	7 dpo groups in the GM muscle	37404
@NP	7 dpo groups	37404
@NP	the GM muscle	37420
@NP	no statistical differences	37435
@NP	groups	37481
@NP	Histological results	37489
@NP	the effect of cell transplantation	37531
@NP	the effect	37531
@NP	cell transplantation	37545
@NP	the damaged spinal cord tissue	37569
@NP	we	37601
@NP	the whole amount	37615
@NP	spared tissue	37635
@NP	the neuronal survival	37650
@NP	the reactivity of both astroglial and microglial cells at 42 dpo	37677
@NP	the reactivity	37677
@NP	both astroglial and microglial cells at 42 dpo	37695
@NP	both astroglial and microglial cells	37695
@NP	42 dpo	37735
@NP	all these analyses	37746
@NP	we	37765
@NP	the acute and subacute transplant groups	37790
@NP	the acute transplants -LRB- Fig. 5A -RRB-	37835
@NP	the acute transplants	37835
@NP	Fig. 5A	37858
@NP	the amount of spinal cord	37868
@NP	the amount	37868
@NP	spinal cord	37882
@NP	tissue	37901
@NP	the two cell-treated groups	37922
@NP	the vehicle-injected group	37958
@NP	two-way ANOVA : F2 ,399 = 44.82 , P	37986
@NP	two-way ANOVA : F2 ,399 = 44.82	37986
@NP	two-way ANOVA	37986
@NP	F2 ,399 = 44.82	38001
@NP	F2 ,399	38001
@NP	44.82	38010
@NP	P	38017
@NP	0.0001	38021
@NP	MSC injection	38045
@NP	more tissue	38083
@NP	both rostral and caudal areas	38098
@NP	rostral	38103
@NP	caudal areas	38115
@NP	the epicenter	38131
@NP	the OEC grafted	38149
@NP	the OEC	38149
@NP	group tissue preservation	38165
@NP	the caudal region	38215
@NP	The same analysis for subacute transplants -LRB- Fig. 5B -RRB-	38234
@NP	The same analysis for subacute transplants	38234
@NP	The same analysis	38234
@NP	subacute transplants	38256
@NP	Fig. 5B	38278
@NP	a higher percentage of spared tissue	38299
@NP	a higher percentage	38299
@NP	spared tissue	38322
@NP	cell-treated groups	38344
@NP	the control	38372
@NP	significant differences in rostral	38390
@NP	significant differences	38390
@NP	rostral	38417
@NP	caudal segments between 1 and 2	38429
@NP	caudal segments	38429
@NP	1 and 2	38453
@NP	the epicenter	38469
@NP	two-way ANOVA : F2 ,304 = 40.63 , P	38484
@NP	two-way ANOVA : F2 ,304 = 40.63	38484
@NP	two-way ANOVA	38484
@NP	F2 ,304 = 40.63	38499
@NP	F2 ,304	38499
@NP	40.63	38508
@NP	P	38515
@NP	0.0001	38519
@NP	the center of the injury	38531
@NP	the center	38531
@NP	the injury	38545
@NP	the epicenter	38564
@NP	there	38579
@NP	no differences between groups in the amount of spared tissue	38590
@NP	no differences	38590
@NP	groups in the amount of spared tissue	38613
@NP	groups	38613
@NP	the amount of spared tissue	38623
@NP	the amount	38623
@NP	spared tissue	38637
@NP	acute and delayed treatment	38663
@NP	the percentage of spared tissue volume	38692
@NP	the percentage	38692
@NP	spared tissue volume	38710
@NP	Fig. 5C	38747
@NP	The results	38757
@NP	a similar amount	38774
@NP	protected tissue	38794
@NP	acute and delayed injection	38819
@NP	vehicle -LRB- VE -- 0 dpo : 72.8 ± 2.8 % ; VE -- 7 dpo : 72.7 ± 2.2 % -RRB-	38850
@NP	vehicle	38850
@NP	VE	38859
@NP	0 dpo : 72.8 ± 2.8 % ; VE -- 7 dpo : 72.7 ± 2.2 %	38862
@NP	0 dpo	38862
@NP	72.8 ± 2.8 % ; VE -- 7 dpo : 72.7 ± 2.2 %	38869
@NP	72.8 ± 2.8 %	38869
@NP	72.8 ±	38869
@NP	2.8 %	38876
@NP	VE -- 7 dpo	38882
@NP	VE	38882
@NP	7 dpo	38885
@NP	72.7 ± 2.2 %	38892
@NP	72.7 ±	38892
@NP	2.2 %	38899
@NP	MSC -LRB- MSC -- 0 dpo : 83.8 ± 2.8 % ; MSC -- 7 dpo : 80.8 ± 2.6 % -RRB-	38906
@NP	MSC	38906
@NP	MSC	38911
@NP	0 dpo : 83.8 ± 2.8 % ; MSC -- 7 dpo : 80.8 ± 2.6 %	38915
@NP	0 dpo	38915
@NP	83.8 ± 2.8 % ; MSC -- 7 dpo : 80.8 ± 2.6 %	38922
@NP	83.8 ± 2.8 %	38922
@NP	83.8 ±	38922
@NP	2.8 %	38929
@NP	MSC -- 7 dpo	38935
@NP	MSC	38935
@NP	7 dpo	38939
@NP	80.8 ± 2.6 %	38946
@NP	80.8 ±	38946
@NP	2.6 %	38953
@NP	OEC -LRB- OEC -- 0 dpo : 80.4 ± 2.8 % ; OEC -- 7 dpo : 85.1 ± 2.4 % -RRB-	38963
@NP	OEC	38963
@NP	OEC	38968
@NP	0 dpo : 80.4 ± 2.8 % ; OEC -- 7 dpo : 85.1 ± 2.4 %	38972
@NP	0 dpo	38972
@NP	80.4 ± 2.8 % ; OEC -- 7 dpo : 85.1 ± 2.4 %	38979
@NP	80.4 ± 2.8 %	38979
@NP	80.4 ±	38979
@NP	2.8 %	38986
@NP	OEC -- 7 dpo	38992
@NP	OEC	38992
@NP	7 dpo	38997
@NP	85.1 ± 2.4 %	39004
@NP	85.1	39004
@NP	± 2.4 %	39009
@NP	respect to neuron survival	39023
@NP	respect	39023
@NP	neuron survival	39034
@NP	the number of NeuN + cells in the two ventral horns of each analysed section	39051
@NP	the number	39051
@NP	NeuN + cells in the two ventral horns of each analysed section	39065
@NP	NeuN + cells	39065
@NP	the two ventral horns of each analysed section	39080
@NP	the two ventral horns	39080
@NP	each analysed section	39105
@NP	Fig. 6A	39140
@NP	Higher numbers of NeuN + cells	39150
@NP	Higher numbers	39150
@NP	NeuN + cells	39168
@NP	NeuN	39168
@NP	cells	39174
@NP	the treated groups	39194
@NP	both acute and subacute transplantation time vs. the respective control groups	39216
@NP	both acute and subacute transplantation time	39216
@NP	the respective control groups	39265
@NP	the acute transplants -LRB- Fig. 6B -RRB-	39299
@NP	the acute transplants	39299
@NP	Fig. 6B	39322
@NP	both cell types	39332
@NP	neurons	39361
@NP	both rostral and caudal segments	39372
@NP	both rostral	39372
@NP	caudal segments	39389
@NP	the distal transplantation site	39412
@NP	two-way ANOVA : F2 ,300 = 5.69	39445
@NP	two-way ANOVA	39445
@NP	F2 ,300 = 5.69	39460
@NP	F2 ,300	39460
@NP	5.69	39469
@NP	P < 0.038	39475
@NP	P	39475
@NP	< 0.038	39477
@NP	<	39477
@NP	0.038	39479
@NP	the case of subacute transplants -LRB- Fig. 6C -RRB-	39490
@NP	the case	39490
@NP	subacute transplants -LRB- Fig. 6C -RRB-	39502
@NP	subacute transplants	39502
@NP	Fig. 6C	39524
@NP	this neuroprotective effect	39534
@NP	caudal	39580
@NP	the epicenter -LRB- twoway ANOVA : F2 ,282 = 13.52 , P < 0.0001 -RRB-	39590
@NP	the epicenter	39590
@NP	twoway ANOVA : F2 ,282 = 13.52 , P	39605
@NP	twoway ANOVA : F2 ,282 = 13.52	39605
@NP	twoway ANOVA	39605
@NP	F2 ,282 = 13.52	39619
@NP	F2 ,282	39619
@NP	13.52	39628
@NP	P	39635
@NP	0.0001	39639
@NP	more neurons	39657
@NP	the distal injection segments	39686
@NP	no labeled neurons	39717
@NP	the epicenter of the injury in any experimental group	39750
@NP	the epicenter	39750
@NP	the injury in any experimental group	39767
@NP	the injury	39767
@NP	any experimental group	39781
@NP	injury	39811
@NP	a larger cord area	39818
@NP	astrocytes in the white matter at the epicenter section	39853
@NP	astrocytes	39853
@NP	the white matter at the epicenter section	39867
@NP	the white matter	39867
@NP	the epicenter section	39887
@NP	both distal segments	39917
@NP	The fraction of GFAP-labeled area	39939
@NP	The fraction	39939
@NP	GFAP-labeled area	39955
@NP	all the groups	39988
@NP	the acute -LRB- Fig. 7B -RRB- or subacute -LRB- Fig. 7C -RRB-	40021
@NP	the acute	40021
@NP	Fig. 7B	40032
@NP	subacute	40044
@NP	Fig. 7C	40054
@NP	transplantation	40063
@NP	the area occupied by Iba1-labeled microglia/macrophages	40091
@NP	the area	40091
@NP	Iba1-labeled microglia/macrophages	40112
@NP	the epicenter	40161
@NP	the distal sections	40183
@NP	acute transplantation -LRB- Fig. 8B -RRB-	40210
@NP	acute transplantation	40210
@NP	Fig. 8B	40233
@NP	a significant reduction of Iba1-labeled area	40243
@NP	a significant reduction	40243
@NP	Iba1-labeled area	40270
@NP	both MSC and OEC treated groups	40305
@NP	both MSC	40305
@NP	OEC treated groups	40318
@NP	comparison	40340
@NP	the vehicle group in the caudal section -LRB- MSC -- 0 dpo vs.	40356
@NP	the vehicle group	40356
@NP	the caudal section -LRB- MSC -- 0 dpo vs.	40377
@NP	the caudal section	40377
@NP	MSC	40397
@NP	0 dpo	40401
@NP	0	40401
@NP	dpo	40403
@NP	vs.	40407
@NP	VE -- 0 dpo : Bonferroni t = 2.62 , P < 0.05 ; OEC -- 0 dpo vs.	40411
@NP	VE	40411
@NP	0 dpo : Bonferroni t = 2.62 , P < 0.05 ;	40415
@NP	0 dpo	40415
@NP	Bonferroni t = 2.62 , P < 0.05	40422
@NP	Bonferroni t = 2.62 , P <	40422
@NP	Bonferroni t	40422
@NP	= 2.62 , P <	40435
@NP	2.62 , P	40437
@NP	2.62	40437
@NP	P	40443
@NP	0.05	40447
@NP	OEC	40453
@NP	0 dpo	40457
@NP	vs.	40463
@NP	VE -- 0 dpo : Bonferroni t = 2.69 , P < 0.05 -RRB- .	40467
@NP	VE	40467
@NP	0 dpo : Bonferroni t = 2.69 , P < 0.05 -RRB-	40470
@NP	0 dpo	40470
@NP	Bonferroni t = 2.69 , P < 0.05 -RRB-	40477
@NP	Bonferroni t = 2.69	40477
@NP	Bonferroni t	40477
@NP	= 2.69	40490
@NP	P < 0.05	40498
@NP	P <	40498
@NP	P	40498
@NP	0.05	40502
@NP	the other hand	40512
@NP	subacute treatment -LRB- Fig. 8C -RRB-	40534
@NP	subacute treatment	40534
@NP	Fig. 8C	40554
@NP	this reduction in the Iba1 + area	40563
@NP	this reduction	40563
@NP	the Iba1 + area	40581
@NP	the Iba1	40581
@NP	area	40591
@NP	both rostral -LRB- MSC -- 7 dpo vs.	40612
@NP	both rostral	40612
@NP	MSC	40626
@NP	7 dpo	40630
@NP	7	40630
@NP	dpo	40632
@NP	vs.	40636
@NP	VE -- 7 dpo : Bonferroni t = 2.51 , P < 0.05 ; OEC -- 7 dpo vs.	40640
@NP	VE	40640
@NP	7 dpo : Bonferroni t = 2.51 , P < 0.05 ;	40643
@NP	7 dpo	40643
@NP	Bonferroni t = 2.51 , P < 0.05	40650
@NP	Bonferroni t = 2.51 , P <	40650
@NP	Bonferroni t	40650
@NP	= 2.51 , P <	40663
@NP	2.51 , P	40665
@NP	2.51	40665
@NP	P	40671
@NP	0.05	40675
@NP	OEC	40681
@NP	7 dpo	40685
@NP	vs.	40691
@NP	VE	40695
@NP	7 dpo : Bonferroni t = 3.63 , P < 0.01 -RRB-	40698
@NP	7 dpo	40698
@NP	Bonferroni t = 3.63 , P < 0.01 -RRB-	40705
@NP	Bonferroni t = 3.63	40705
@NP	Bonferroni t	40705
@NP	3.63	40720
@NP	P < 0.01	40726
@NP	P <	40726
@NP	P	40726
@NP	0.01	40730
@NP	caudal sections -LRB- MSC -- 7 dpo	40740
@NP	caudal sections	40740
@NP	MSC -- 7 dpo	40757
@NP	MSC	40757
@NP	7 dpo	40761
@NP	vs.	40767
@NP	VE -- 7 dpo : Bonferroni t = 2.93 , P < 0.05 ; OEC -- 7 dpo vs.	40771
@NP	VE	40771
@NP	7 dpo : Bonferroni t = 2.93 , P < 0.05 ;	40774
@NP	7 dpo	40774
@NP	Bonferroni t = 2.93 , P < 0.05	40781
@NP	Bonferroni t = 2.93 , P <	40781
@NP	Bonferroni t	40781
@NP	= 2.93 , P <	40794
@NP	2.93 , P	40796
@NP	2.93	40796
@NP	P	40802
@NP	0.05	40806
@NP	OEC	40812
@NP	7 dpo	40816
@NP	vs.	40822
@NP	VE -- 7 dpo : Bonferroni t = 2.52 , P < 0.05 -RRB- .	40826
@NP	VE	40826
@NP	7 dpo : Bonferroni t = 2.52 , P < 0.05 -RRB-	40829
@NP	7 dpo	40829
@NP	Bonferroni t = 2.52 , P < 0.05 -RRB-	40836
@NP	Bonferroni t = 2.52	40836
@NP	Bonferroni t	40836
@NP	= 2.52	40849
@NP	P < 0.05	40857
@NP	P <	40857
@NP	P	40857
@NP	0.05	40861
@NP	All these results	40868
@NP	transplantation of MSCs or OECs	40900
@NP	transplantation	40900
@NP	MSCs or OECs	40919
@NP	the evolution of the injury	40939
@NP	the evolution	40939
@NP	the injury	40956
@NP	the amount of damaged tissue , neuronal death and microglial/macrophage reaction	40977
@NP	the amount	40977
@NP	damaged tissue , neuronal death and microglial/macrophage reaction	40991
@NP	damaged tissue , neuronal death	40991
@NP	microglial/macrophage reaction	41026
@NP	no statistical differences	41072
@NP	type of cells in any of the histological analyses	41118
@NP	type	41118
@NP	cells in any of the histological analyses	41126
@NP	cells	41126
@NP	any of the histological analyses	41135
@NP	any	41135
@NP	the histological analyses	41142
@NP	Discussion Cell therapy for SCI	41170
@NP	Discussion Cell therapy	41170
@NP	SCI	41198
@NP	a widely debatable issue	41205
@NP	some experimental studies	41239
@NP	therapeutic effects	41276
@NP	other	41297
@NP	no significant improvement	41312
@NP	the appearance	41348
@NP	undesirable secondary effects	41366
@NP	Sykov	41397
@NP	a et al. , 2006	41403
@NP	a et al.	41403
@NP	2006	41413
@NP	Sahni & Kessler , 2010	41419
@NP	Sahni & Kessler	41419
@NP	2010	41436
@NP	Hern andez et al. , 2011	41442
@NP	Hern andez	41442
@NP	et al. , 2011	41453
@NP	et al.	41453
@NP	2011	41461
@NP	Mothe & Tator , 2012	41467
@NP	Mothe & Tator	41467
@NP	2012	41482
@NP	Several factors	41489
@NP	the potential therapeutic benefit of cell grafts	41519
@NP	the potential therapeutic benefit	41519
@NP	cell grafts	41556
@NP	a SCI	41578
@NP	the nature	41593
@NP	the cells , age and donor variation	41607
@NP	injury type and severity	41643
@NP	cell culture methods	41669
@NP	cell delivery methods	41691
@NP	the specific techniques	41718
@NP	the outcomes	41759
@NP	it	41785
@NP	published works	41811
@NP	different laboratories	41832
@NP	this context	41859
@NP	we	41873
@NP	the effects	41893
@NP	MSC and OEC transplantation , two of the most promising cell types	41908
@NP	MSC and OEC transplantation	41908
@NP	two of the most promising cell types	41937
@NP	two	41937
@NP	the most promising cell types	41944
@NP	SCI repair	41978
@NP	the best option for spinal cord contusion injuries	42012
@NP	the best option	42012
@NP	spinal cord contusion injuries	42032
@NP	The results of this study	42064
@NP	The results	42064
@NP	this study	42079
@NP	a similar amount	42095
@NP	tissue protection and neuronal survival provided by grafted MSCs and OECs	42115
@NP	tissue protection	42115
@NP	neuronal survival provided by grafted MSCs and OECs	42137
@NP	neuronal survival	42137
@NP	grafted MSCs and OECs	42167
@NP	acute and subacute treatments	42198
@NP	the increased tissue preservation	42244
@NP	significant improvement in functional outcomes	42301
@NP	significant improvement	42301
@NP	functional outcomes	42328
@NP	the animals treated with OECs	42351
@NP	the animals	42351
@NP	OECs	42376
@NP	The engraftment with MSCs	42382
@NP	The engraftment	42382
@NP	MSCs	42403
@NP	higher hyper-reflexia	42416
@NP	the acute transplant	42451
@NP	the animals	42476
@NP	higher speed treadmill running and recovery of MEPs	42496
@NP	higher speed treadmill running	42496
@NP	higher speed treadmill	42496
@NP	recovery of MEPs	42531
@NP	recovery	42531
@NP	MEPs	42543
@NP	the grafted cell survival study	42562
@NP	a fast reduction	42603
@NP	2 -- 3 weeks of both MSCs and OECs	42629
@NP	2	42629
@NP	3 weeks of both MSCs and OECs	42631
@NP	3 weeks	42631
@NP	both MSCs and OECs	42642
@NP	the injured spinal cord	42668
@NP	Thoracic SCI by a moderate contusion	42693
@NP	Thoracic SCI	42693
@NP	a moderate contusion	42709
@NP	a drastic destruction	42739
@NP	the spinal cord	42764
@NP	practically all the parenchyma at the epicenter	42797
@NP	practically all the parenchyma	42797
@NP	the epicenter	42831
@NP	tissue damage	42857
@NP	several spinal cord segments	42877
@NP	This affectation	42907
@NP	the transmission of the motor-descending information	42933
@NP	the transmission	42933
@NP	the motor-descending information	42953
@NP	the abolition of MEPs	42999
@NP	the abolition	42999
@NP	MEPs	43016
@NP	marked locomotor deficits	43035
@NP	a reduced score	43079
@NP	the BBB scale	43098
@NP	the overground walking skills	43126
@NP	the rats -LRB- Basso et al. , 1995 -RRB-	43159
@NP	the rats	43159
@NP	Basso	43169
@NP	et al. , 1995	43175
@NP	et al.	43175
@NP	1995	43183
@NP	a decrease	43190
@NP	the speed	43204
@NP	a treadmill and uncoordinated locomotor pattern	43225
@NP	McEwen & Springer , 2006 ; Redondo-Castro et al. , 2013	43274
@NP	McEwen & Springer	43274
@NP	2006 ; Redondo-Castro et al.	43293
@NP	2006	43293
@NP	Redondo-Castro et al.	43299
@NP	Redondo-Castro	43299
@NP	et al.	43314
@NP	2013	43322
@NP	The partial protection	43329
@NP	spinal cord tissue by MSC or OEC transplantation after the injury	43355
@NP	spinal cord tissue	43355
@NP	MSC or OEC transplantation after the injury	43377
@NP	MSC or OEC transplantation	43377
@NP	the injury	43410
@NP	improved recovery of overground locomotion or gait coordination	43442
@NP	improved recovery	43442
@NP	overground locomotion or gait coordination	43463
@NP	Only an improvement in the running speed	43507
@NP	Only an improvement	43507
@NP	the running speed	43530
@NP	the acute MSC	43564
@NP	transplanted rats	43578
@NP	The slight enhancement of motor performance provided by the acute MSC graft	43597
@NP	The slight enhancement	43597
@NP	motor performance provided by the acute MSC graft	43623
@NP	motor performance	43623
@NP	the acute MSC graft	43653
@NP	the recovery of responses	43691
@NP	the recovery	43691
@NP	responses	43707
@NP	MEPs observed in these animals	43720
@NP	MEPs	43720
@NP	these animals	43737
@NP	this recovery of MEPs	43766
@NP	this recovery	43766
@NP	MEPs	43783
@NP	comparison	43799
@NP	intact animals	43813
@NP	the BBB score achieved by the acute MSC treated group	43833
@NP	the BBB score	43833
@NP	the acute MSC treated group	43859
@NP	the acute MSC	43859
@NP	group	43881
@NP	the other groups	43902
@NP	A 200-Kdyn contusion injury	43920
@NP	the ventral and lateral funiculi	43957
@NP	the white matter -LRB- Cao et al. , 2005 -RRB-	43993
@NP	the white matter	43993
@NP	Cao	44011
@NP	et al. , 2005	44015
@NP	et al.	44015
@NP	2005	44023
@NP	The ventrolateral white matter	44030
@NP	descending pathways	44070
@NP	the control of hindlimb motor function	44104
@NP	the control	44104
@NP	hindlimb motor function	44119
@NP	the reticulospinal tract	44147
@NP	Jones & Yang	44173
@NP	1985	44187
@NP	locomotion and MEP responses	44228
@NP	Magnuson et al. , 1999 ; Loy et al. , 2002 ; Cao et al. , 2005	44258
@NP	Magnuson	44258
@NP	et al. , 1999 ; Loy et al. , 2002 ; Cao et al. , 2005	44267
@NP	et al. , 1999	44267
@NP	et al.	44267
@NP	1999	44275
@NP	Loy et al. , 2002	44281
@NP	Loy	44281
@NP	et al. , 2002	44285
@NP	et al.	44285
@NP	2002	44293
@NP	Cao et al. , 2005	44299
@NP	Cao	44299
@NP	et al. , 2005	44303
@NP	et al.	44303
@NP	2005	44311
@NP	our study	44321
@NP	MSC or OEC transplantation	44332
@NP	cord tissue preservation at the center of the injury	44388
@NP	cord tissue preservation	44388
@NP	the center of the injury	44416
@NP	the center	44416
@NP	the injury	44430
@NP	the ventrolateral white matter	44456
@NP	the gross locomotion performance	44527
@NP	the other hand	44564
@NP	SCI	44580
@NP	an amplification of the spinal reflex activity in segments	44592
@NP	an amplification	44592
@NP	the spinal reflex activity in segments	44612
@NP	the spinal reflex activity	44612
@NP	segments	44642
@NP	the lesion	44661
@NP	This hyper-reflexia	44673
@NP	a consequence	44696
@NP	the loss	44713
@NP	inhibitory descending pathways -LRB- Calancie et al. , 1993 -RRB-	44725
@NP	inhibitory descending pathways	44725
@NP	Calancie	44757
@NP	et al. , 1993	44766
@NP	et al.	44766
@NP	1993	44774
@NP	changes in spinal neurons excitability -LRB- Chen et al. , 2001 -RRB-	44784
@NP	changes	44784
@NP	spinal neurons excitability -LRB- Chen et al. , 2001 -RRB-	44795
@NP	spinal neurons excitability	44795
@NP	Chen	44824
@NP	et al. , 2001	44829
@NP	et al.	44829
@NP	2001	44837
@NP	Transplantation of MSC , independently of the time of injection ,	44844
@NP	Transplantation	44844
@NP	MSC	44863
@NP	the time of injection	44885
@NP	the time	44885
@NP	injection	44897
@NP	higher hyper-reflexia	44916
@NP	OEC transplanted	44946
@NP	OEC	44946
@NP	control injured rats	44970
@NP	The increase in spinal reflexes	44992
@NP	The increase	44992
@NP	spinal reflexes	45008
@NP	the recovery of locomotion	45042
@NP	the recovery	45042
@NP	locomotion	45058
@NP	SCI -LRB- Pearson , 2001 -RRB-	45075
@NP	SCI	45075
@NP	Pearson	45080
@NP	2001	45089
@NP	fact	45099
@NP	functional recovery after incomplete SCI	45105
@NP	functional recovery	45105
@NP	incomplete SCI	45131
@NP	the increase of spinal H reflex responses -LRB- Lee et al. , 2005 -RRB-	45168
@NP	the increase	45168
@NP	spinal H reflex responses -LRB- Lee et al. , 2005 -RRB-	45184
@NP	spinal H reflex responses	45184
@NP	Lee	45211
@NP	et al. , 2005	45215
@NP	et al.	45215
@NP	2005	45223
@NP	treadmill conditions	45236
@NP	the activation of afferent inputs	45258
@NP	the activation	45258
@NP	afferent inputs	45276
@NP	the locomotion movements in spinalized animals -LRB- Whelan , 1996 -RRB-	45301
@NP	the locomotion movements	45301
@NP	spinalized animals -LRB- Whelan , 1996 -RRB-	45329
@NP	spinalized animals	45329
@NP	Whelan	45349
@NP	1996	45357
@NP	the exacerbated hyper-reflexia	45370
@NP	the sensitivity of spinal circuitries	45414
@NP	the sensitivity	45414
@NP	spinal circuitries	45433
@NP	afferent inputs	45455
@NP	better locomotion recovery -LRB- Lee et al. , 2005 ; Joon et al. , 2009 -RRB-	45482
@NP	better locomotion recovery	45482
@NP	Lee	45510
@NP	et al. , 2005 ; Joon et al. , 2009	45514
@NP	et al.	45514
@NP	2005 ; Joon et al.	45522
@NP	2005	45522
@NP	Joon et al.	45528
@NP	Joon	45528
@NP	et al.	45533
@NP	2009	45541
@NP	The increased hyper-reflexia	45548
@NP	the acute MSC grafted rats together with the partial recovery of MEPs	45580
@NP	the acute MSC	45580
@NP	rats	45602
@NP	the partial recovery of MEPs	45621
@NP	the partial recovery	45621
@NP	MEPs	45645
@NP	the improvement of these animals	45662
@NP	the improvement	45662
@NP	these animals	45681
@NP	the treadmill testing	45698
@NP	the sensory perception	45731
@NP	no differences between treatments	45755
@NP	no differences	45755
@NP	treatments	45778
@NP	the algesimetry tests	45803
@NP	the cell grafts	45835
@NP	the increased hyperalgesia	45866
@NP	injury	45899
@NP	they	45907
@NP	hypersensitivity	45929
@NP	mechanical and thermal stimuli	45949
@NP	respect	45985
@NP	injured rats	46004
@NP	a detrimental effect	46018
@NP	other cell types such as neural stem cells -LRB- Hofstetter et al. , 2005 -RRB-	46053
@NP	other cell types	46053
@NP	neural stem cells -LRB- Hofstetter et al. , 2005 -RRB-	46078
@NP	neural stem cells	46078
@NP	Hofstetter	46097
@NP	et al. , 2005	46108
@NP	et al.	46108
@NP	2005	46116
@NP	The histological results	46123
@NP	the transplantation of MSCs or OECs after SCI	46158
@NP	the transplantation	46158
@NP	MSCs or OECs after SCI	46181
@NP	MSCs or OECs	46181
@NP	SCI	46200
@NP	tissue damage	46231
@NP	more	46259
@NP	tissue and neuronal survival of some segments both distal and rostral	46271
@NP	tissue and neuronal survival of some segments	46271
@NP	tissue and neuronal survival	46271
@NP	some segments	46303
@NP	distal and rostral	46322
@NP	distal	46322
@NP	rostral	46333
@NP	the epicenter of the injury	46346
@NP	the epicenter	46346
@NP	the injury	46363
@NP	There	46375
@NP	no significant differences between acute and subacute cell transplants	46386
@NP	no significant differences	46386
@NP	acute and subacute cell transplants	46421
@NP	the lesion epicenter	46475
@NP	the cord tissue	46496
@NP	all the SCI groups	46539
@NP	the SCI groups	46543
@NP	the SCI	46543
@NP	groups	46551
@NP	the number of engrafted cells into the epicenter	46565
@NP	the number	46565
@NP	cells	46589
@NP	the epicenter	46600
@NP	the tissue damage	46648
@NP	The different types of lesion	47033
@NP	The different types	47033
@NP	lesion	47056
@NP	these discrepancies	47089
@NP	tissue preservation	47123
@NP	a higher number of neurons	47144
@NP	a higher number	47144
@NP	neurons	47163
@NP	cell transplantation	47186
@NP	areas surrounding the epicenter	47210
@NP	areas	47210
@NP	the epicenter	47228
@NP	The neuroprotection provided by the engrafted cells	47243
@NP	The neuroprotection	47243
@NP	the engrafted cells	47275
@NP	the	47275
@NP	cells	47289
@NP	an indirect effect	47304
@NP	paracrine action	47340
@NP	secretion of trophic factors	47362
@NP	secretion	47362
@NP	trophic factors	47375
@NP	both MSCs and OECs -LRB- Franssen et al. , 2007 ; Wright et al. , 2011 -RRB-	47394
@NP	both MSCs and OECs	47394
@NP	Franssen	47414
@NP	et al. , 2007 ; Wright et al. , 2011	47423
@NP	et al.	47423
@NP	2007 ; Wright et al.	47431
@NP	2007	47431
@NP	Wright et al.	47437
@NP	Wright	47437
@NP	et al.	47444
@NP	2011	47452
@NP	the survival of neurons in the segments of the thoracic injury	47478
@NP	the survival	47478
@NP	neurons in the segments of the thoracic injury	47494
@NP	neurons	47494
@NP	the segments of the thoracic injury	47505
@NP	the segments	47505
@NP	the thoracic injury	47521
@NP	low relevance for the locomotor performance	47554
@NP	low relevance	47554
@NP	the locomotor performance	47572
@NP	this neuroprotective action	47599
@NP	the autonomic functions controlled by the injured spinal cord segments	47651
@NP	the autonomic functions	47651
@NP	the injured spinal cord segments	47689
@NP	the other hand	47726
@NP	we	47742
@NP	the reduction	47755
@NP	microglia/macrophage reactivity caused by both MSC and OEC transplants	47772
@NP	microglia/macrophage reactivity	47772
@NP	both MSC and OEC transplants	47814
@NP	MSC	47819
@NP	OEC transplants	47827
@NP	L opez-Vales	47873
@NP	et al. , 2004a , b ; Chuah et al. , 2011 ; Nakajima et al. , 2012	47886
@NP	et al.	47886
@NP	2004a , b ; Chuah et al. , 2011 ; Nakajima et al.	47894
@NP	2004a , b	47894
@NP	2004a	47894
@NP	b	47900
@NP	Chuah et al. , 2011	47903
@NP	Chuah	47903
@NP	et al. , 2011	47909
@NP	et al.	47909
@NP	2011	47917
@NP	Nakajima et al.	47923
@NP	Nakajima	47923
@NP	et al.	47932
@NP	2012	47940
@NP	This modulatory effect of the grafted cells	47947
@NP	This modulatory effect	47947
@NP	the grafted cells	47973
@NP	reduction of detrimental inflammatory reaction and secretion of cytokines	48005
@NP	reduction	48005
@NP	detrimental inflammatory reaction and secretion	48018
@NP	cytokines	48069
@NP	the transplantation of MSCs and OECs	48086
@NP	the transplantation	48086
@NP	MSCs and OECs	48109
@NP	the amount of damaged tissue	48143
@NP	the amount	48143
@NP	damaged tissue	48157
@NP	neurons	48197
@NP	the spared tissue	48208
@NP	the chronic microglial / macrophage presence	48238
@NP	the chronic microglial	48238
@NP	macrophage presence	48262
@NP	Localization of the transplanted cells	48283
@NP	Localization	48283
@NP	the transplanted cells	48299
@NP	similar amounts of MSCs and OECs	48332
@NP	similar amounts	48332
@NP	MSCs and OECs	48351
@NP	the first week	48372
@NP	injection	48393
@NP	a marked decrease in the GFP signal	48408
@NP	a marked decrease	48408
@NP	the GFP signal	48429
@NP	the two following weeks	48453
@NP	the survival of transplanted cells within the spinal cord	48503
@NP	the survival	48503
@NP	transplanted cells within the spinal cord	48519
@NP	transplanted cells	48519
@NP	the spinal cord	48545
@NP	cell type	48589
@NP	the spinal cord environment after contusion	48621
@NP	the spinal cord environment	48621
@NP	contusion	48655
@NP	Barakat	48698
@NP	et al. , 2005	48706
@NP	et al.	48706
@NP	2005	48714
@NP	Pearse et al. , 2007	48720
@NP	Pearse	48720
@NP	et al. , 2007	48727
@NP	et al.	48727
@NP	2007	48735
@NP	Abrams et al. , 2009	48741
@NP	Abrams	48741
@NP	et al. , 2009	48748
@NP	et al.	48748
@NP	2009	48756
@NP	Nakajima et al. , 2012	48762
@NP	Nakajima	48762
@NP	et al. , 2012	48771
@NP	et al.	48771
@NP	2012	48779
@NP	immunoprivileged properties of MSCs	48795
@NP	immunoprivileged properties	48795
@NP	MSCs	48826
@NP	Nauta & Fibbe	48847
@NP	2009	48862
@NP	reduced survival	48869
@NP	MSCs	48899
@NP	rats	48909
@NP	Abrams	48915
@NP	et al. , 2009	48922
@NP	et al.	48922
@NP	2009	48930
@NP	human donors	48940
@NP	Himes et al. , 2006	48954
@NP	Himes	48954
@NP	et al.	48960
@NP	2006	48968
@NP	the limited survival of the OEC transplant	49015
@NP	the limited survival	49015
@NP	the OEC transplant	49039
@NP	contusion injuries	49083
@NP	Barakat	49103
@NP	et al. , 2005 ; Pearse et al. , 2007	49111
@NP	et al.	49111
@NP	2005 ; Pearse et al.	49119
@NP	2005	49119
@NP	Pearse et al.	49125
@NP	Pearse	49125
@NP	et al.	49132
@NP	2007	49140
@NP	dorsal column lesion	49150
@NP	Roet	49172
@NP	et al. , 2012	49177
@NP	et al.	49177
@NP	2012	49185
@NP	a recent work	49195
@NP	we	49210
@NP	allogenic transplantation of both MSCs and OECs	49224
@NP	allogenic transplantation	49224
@NP	both MSCs and OECs	49253
@NP	the expression of immune rejection-associated genes	49280
@NP	the expression	49280
@NP	immune rejection-associated genes	49298
@NP	acute and delayed transplantation -LRB- Torres-Esp ın et al. , 2013 -RRB-	49338
@NP	acute and delayed transplantation	49338
@NP	Torres-Esp ın	49373
@NP	et al. , 2013	49387
@NP	et al.	49387
@NP	2013	49395
@NP	an immunogenic reaction against these cells	49416
@NP	an immunogenic reaction	49416
@NP	these cells	49448
@NP	More work	49461
@NP	work	49466
@NP	the reason	49494
@NP	the poor grafted cell survival	49509
@NP	the poor	49509
@NP	cell survival	49526
@NP	immunosuppressive co-treatments	49557
@NP	our data	49603
@NP	no differences	49617
@NP	time-survival between MSCs and OECs	49635
@NP	time-survival	49635
@NP	MSCs and OECs	49657
@NP	the survival of the grafted cells	49692
@NP	the survival	49692
@NP	the grafted cells	49708
@NP	the treatment success	49749
@NP	this factor	49772
@NP	the differences	49801
@NP	MSC and OEC transplants	49831
@NP	MSC vs.	49856
@NP	MSC	49856
@NP	vs.	49860
@NP	OEC for spinal cord contusion injuries Our findings	49864
@NP	OEC	49864
@NP	spinal cord contusion injuries Our findings	49872
@NP	spinal cord contusion injuries	49872
@NP	Our findings	49903
@NP	the capacity of both MSC and OEC grafts	49928
@NP	the capacity	49928
@NP	both MSC and OEC grafts	49944
@NP	MSC	49949
@NP	OEC grafts	49957
@NP	beneficial effects	49979
@NP	spinal cord contusion	50004
@NP	a number of works	50033
@NP	a number	50033
@NP	works	50045
@NP	tissue sparing and functional recovery	50072
@NP	tissue sparing	50072
@NP	MSC transplantation	50116
@NP	contusion injuries	50142
@NP	Chopp	50162
@NP	et al. , 2000	50168
@NP	et al.	50168
@NP	2000	50176
@NP	Hofstetter et al. , 2002	50182
@NP	Hofstetter	50182
@NP	et al. , 2002	50193
@NP	et al.	50193
@NP	2002	50201
@NP	Neuhuber et al. , 2005	50207
@NP	Neuhuber	50207
@NP	et al. , 2005	50216
@NP	et al.	50216
@NP	2005	50224
@NP	Himes et al. , 2006	50230
@NP	Himes	50230
@NP	et al. , 2006	50236
@NP	et al.	50236
@NP	2006	50244
@NP	Quertainmont et al. , 2012	50250
@NP	Quertainmont	50250
@NP	et al. , 2012	50263
@NP	et al.	50263
@NP	2012	50271
@NP	the effects	50278
@NP	OEC treatment in the contusion model	50311
@NP	OEC treatment	50311
@NP	the contusion model	50328
@NP	Several studies of acute and delayed OEC transplantation after contusion injury	50349
@NP	Several studies	50349
@NP	OEC transplantation	50386
@NP	contusion injury	50412
@NP	no effects	50436
@NP	locomotion recovery	50450
@NP	Pearson	50471
@NP	2001	50480
@NP	Takami	50486
@NP	et al. , 2002	50493
@NP	et al.	50493
@NP	2002	50501
@NP	Resnick et al. , 2003	50507
@NP	Resnick	50507
@NP	et al. , 2003	50515
@NP	et al.	50515
@NP	2003	50523
@NP	Barakat et al. , 2005	50529
@NP	Barakat	50529
@NP	et al. , 2005	50537
@NP	et al.	50537
@NP	2005	50545
@NP	Collazos-Castro et al.	50551
@NP	Collazos-Castro	50551
@NP	et al.	50567
@NP	2005	50575
@NP	contrast	50585
@NP	complete transection injuries	50601
@NP	the effects of OECs on axonal growth and functional improvement	50631
@NP	the effects	50631
@NP	OECs on axonal growth and functional improvement	50646
@NP	OECs	50646
@NP	axonal growth and functional improvement	50654
@NP	Li et al. , 1998 ; L opez-Vales et al. , 2006 , 2007 ; Franssen et al. , 2007	50722
@NP	Li et al.	50722
@NP	Li	50722
@NP	et al.	50725
@NP	1998 ; L opez-Vales et al.	50733
@NP	1998	50733
@NP	L opez-Vales et al.	50739
@NP	L opez-Vales	50739
@NP	et al.	50752
@NP	2006	50760
@NP	2007 ; Franssen et al. , 2007	50766
@NP	2007	50766
@NP	Franssen et al. , 2007	50772
@NP	Franssen	50772
@NP	et al. , 2007	50781
@NP	et al.	50781
@NP	2007	50789
@NP	Contusion	50796
@NP	the most complex and severe type of lesion to the spinal cord	50809
@NP	the most complex and severe type	50809
@NP	lesion to the spinal cord	50845
@NP	lesion	50845
@NP	the spinal cord	50855
@NP	the formation	50897
@NP	large cystic cavities , extensive hemorrhage and secondary loss of tissue	50914
@NP	large cystic cavities	50914
@NP	extensive hemorrhage	50937
@NP	secondary loss of tissue	50962
@NP	secondary loss	50962
@NP	tissue	50980
@NP	the hostile environment after contusion	51001
@NP	the hostile environment	51001
@NP	contusion	51031
@NP	the graft survival	51063
@NP	spinal cord contusion	51092
@NP	the most relevant injury model	51128
@NP	it	51163
@NP	the neuropathology of most human SCIs -LRB- Bunge et al. , 1997 -RRB-	51173
@NP	the neuropathology	51173
@NP	most human SCIs	51195
@NP	Bunge	51212
@NP	et al. , 1997	51218
@NP	et al.	51218
@NP	1997	51226
@NP	procurement and expansion	51244
@NP	the MSCs , in addition to the better functional effects	51273
@NP	the MSCs	51273
@NP	the better functional effects	51298
@NP	the MSC	51337
@NP	groups	51353
@NP	them	51366
@NP	cell therapy in spinal cord contusion than OECs	51389
@NP	cell therapy	51389
@NP	spinal cord contusion than OECs	51405
@NP	spinal cord contusion	51405
@NP	OECs	51432
@NP	the early stages of the pathology	51454
@NP	the early stages	51454
@NP	the pathology	51474
@NP	the other hand	51492
@NP	the post-injury time of intervention	51508
@NP	the post-injury time	51508
@NP	intervention	51532
@NP	an important point to consider for cell therapy	51548
@NP	cell therapy	51583
@NP	The earliest times	51597
@NP	damage	51645
@NP	the tissue -LRB- L opez-Vales et al. , 2006 , 2007 -RRB-	51664
@NP	the tissue	51664
@NP	L opez-Vales	51676
@NP	et al. , 2006 , 2007	51689
@NP	et al.	51689
@NP	2006	51697
@NP	2007	51703
@NP	the detrimental ambience during the first days of injury	51719
@NP	the detrimental ambience	51719
@NP	the first days of injury	51751
@NP	the first days	51751
@NP	injury	51769
@NP	the efficacy of the transplant	51789
@NP	the efficacy	51789
@NP	the transplant	51805
@NP	the clinical application of acute cell transplants	51831
@NP	the clinical application	51831
@NP	acute cell transplants	51859
@NP	Some works	51902
@NP	better results	51927
@NP	early cell transplantation	51965
@NP	Hofstetter	51993
@NP	et al. , 2002 ; L opez-Vales et al. , 2006	52004
@NP	et al.	52004
@NP	2002 ; L opez-Vales et al.	52012
@NP	2002	52012
@NP	L opez-Vales et al.	52018
@NP	L opez-Vales	52018
@NP	et al.	52031
@NP	2006	52039
@NP	another	52050
@NP	more positive effects	52068
@NP	delayed treatment -LRB- Nandoe Tewarie et al. , 2009 -RRB-	52107
@NP	delayed treatment	52107
@NP	Nandoe Tewarie	52126
@NP	et al. , 2009	52141
@NP	et al.	52141
@NP	2009	52149
@NP	accordance with our present study for the MSC grafts	52158
@NP	accordance	52158
@NP	our present study for the MSC grafts	52174
@NP	our present study	52174
@NP	the MSC grafts	52196
@NP	the controversial results	52219
@NP	the different experimental conditions	52259
@NP	the type	52332
@NP	cells regarding mechanisms of action	52344
@NP	cells	52344
@NP	mechanisms of action	52360
@NP	mechanisms	52360
@NP	action	52374
@NP	the time treatment window , the number of cells injected	52382
@NP	the time treatment window	52382
@NP	the number of cells injected	52409
@NP	the number	52409
@NP	cells injected	52423
@NP	cells	52423
@NP	possible combined treatments	52442
@NP	the optimal cell therapy strategy for SCI	52507
@NP	the optimal cell therapy strategy	52507
@NP	SCI	52545
@VP	is a promising strategy for clinical application	607
@VP	known as bone marrow-derived ` mesenchymal stem cells '	712
@VP	determine the therapy success and the lack of methodological consensus	956
@VP	is difficult	1062
@VP	were assessed	1302
@VP	assessed	1307
@VP	were studied	1397
@VP	studied	1402
@VP	disappeared in the following 2 weeks	1503
@VP	grafts provided tissue protection after early and delayed transplantation	1592
@VP	provided tissue protection after early and delayed transplantation	1599
@VP	seem a better option than OEC for treatment of contusion injuries	1898
@VP	ascending and descending neural pathways	2192
@VP	to promote repair and recovery from the injury	2273
@VP	promote repair and recovery from the injury	2276
@VP	are glial cells present in the olfactory system	3810
@VP	to guide and support the elongation of newly growing sensory axons	3877
@VP	guide and support the elongation of newly growing sensory axons	3880
@VP	make new synaptic connections -LRB- Raisman , 1985 ; Doucette , 1995 -RRB-	4017
@VP	reduced the volume of injured tissue	4155
@VP	induced improvement in functional outcome	4193
@VP	ıas et al. , 2004 ; L opez-Vales et al. , 2006	4335
@VP	choosing the best option for cell therapy of the contused spinal cord	5697
@VP	contused spinal cord	5746
@VP	were set up from P22 male Sprague -- Dawley rats	5847
@VP	set up from P22 male Sprague -- Dawley rats	5852
@VP	were killed with CO2	5906
@VP	killed with CO2	5911
@VP	were removed for MSC culture and the olfactory bulbs for OEC culture	5963
@VP	removed for MSC culture and the olfactory bulbs for OEC culture	5968
@VP	were placed on cool phosphate-buffered saline -LRB- PBS -RRB-	6084
@VP	placed on cool phosphate-buffered saline -LRB- PBS -RRB-	6089
@VP	were removed	6150
@VP	removed	6155
@VP	were flushed with PBS using a syringe	6187
@VP	flushed with PBS using a syringe	6192
@VP	using a syringe	6209
@VP	was homogenized	6240
@VP	homogenized	6244
@VP	filtered through a 70-µm nylon mesh	6273
@VP	recovered by centrifugation for 10 min at 220 g.	6313
@VP	containing non-adherent cells	6838
@VP	was removed	6868
@VP	removed	6872
@VP	was added	6897
@VP	added	6901
@VP	was near confluence , every 4 -- 5 days	6925
@VP	re-plated at 5000 cells/cm2	7109
@VP	were passaged three -- four times , expanded to 80 -- 90 % of confluence	7144
@VP	passaged three -- four times , expanded to 80 -- 90 % of confluence	7149
@VP	expanded to 80	7176
@VP	were centrifuged for 5 min at 160 g and resuspended in PBS	7456
@VP	centrifuged for 5 min at 160 g and resuspended in PBS	7461
@VP	centrifuged for 5 min at 160 g	7461
@VP	resuspended in PBS	7496
@VP	was assessed as described previously -LRB- Harting et al. , 2008 -RRB-	7729
@VP	assessed as described previously -LRB- Harting et al. , 2008 -RRB-	7733
@VP	described previously -LRB- Harting et al. , 2008 -RRB-	7745
@VP	Harting et al. , 2008	7767
@VP	were fixed for 20 min with 4 % paraformaldehyde in phosphate buffer	7826
@VP	fixed for 20 min with 4 % paraformaldehyde in phosphate buffer	7831
@VP	washed with distilled water	8017
@VP	fixed using 70 % ethanol pre-cooled for 1 h at 4 °C	8082
@VP	using 70 % ethanol pre-cooled for 1 h at 4 °C	8088
@VP	washed	8134
@VP	was stripped off with a fine forceps	8414
@VP	stripped off with a fine forceps	8418
@VP	mechanically dissociated	8584
@VP	coated with poly-L-lysine and incubated in 5 % CO2 at 37 °C	8750
@VP	coated with poly-L-lysine	8750
@VP	incubated in 5 % CO2 at 37 °C	8780
@VP	was DMEM supplemented with 10 % FBS -LRB- Life Technologies -RRB-	8825
@VP	supplemented with 10 % FBS -LRB- Life Technologies -RRB-	8834
@VP	were kept in culture at least for 7 days	8887
@VP	kept in culture at least for 7 days	8892
@VP	using the MACS separation -LRB- Miltenyi Biotec -RRB-	9148
@VP	was at least 75 % determined by immunolabeling against p75 and S100	9204
@VP	determined by immunolabeling against p75 and S100	9221
@VP	used a green fluorescence protein -LRB- GFP -RRB- lentiviral vector	9766
@VP	were transfected with a lentiviral vector encoding for GFP under EF1a promoter	9830
@VP	transfected with a lentiviral vector encoding for GFP under EF1a promoter	9835
@VP	encoding for GFP under EF1a promoter	9872
@VP	plated at 2000 cells/cm2	9934
@VP	incubated with lentiviruses at multiplicity of infection of 10 during 48 h.	9963
@VP	was changed	10056
@VP	changed	10060
@VP	cultured as described above	10082
@VP	described above	10094
@VP	was done at 2	10128
@VP	done at 2	10132
@VP	replaced by complete culture medium and the cells cultured for five more days	10227
@VP	cultured for five more days	10277
@VP	counting for both OEC and MSC cells	10402
@VP	were used	10527
@VP	used	10532
@VP	were housed with free access to food and water at room temperature of 22 2 °C	10550
@VP	housed with free access to food and water at room temperature of 22 2 °C	10555
@VP	was made to expose T6 -- T10 spinous processes	11010
@VP	made to expose T6 -- T10 spinous processes	11014
@VP	to expose T6 -- T10 spinous processes	11019
@VP	expose T6 -- T10 spinous processes	11022
@VP	was performed in T8 -- T9 vertebra	11069
@VP	performed in T8 -- T9 vertebra	11073
@VP	were divided into six groups	11285
@VP	divided into six groups	11290
@VP	suspended in L15 medium -LRB- Life Technologies -RRB- at 50 000 cells/lL	11984
@VP	maintained in ice during the time of surgery	12051
@VP	was about 90 % , as quantified in a Neubauer chamber using trypan blue stain	12141
@VP	quantified in a Neubauer chamber using trypan blue	12159
@VP	using trypan blue	12192
@VP	stain	12210
@VP	injected at the epicenter	12449
@VP	at 2 mm rostrally and caudally	12479
@VP	maintained inside the tissue 3 min after each injection to avoid liquid reflux	12693
@VP	to avoid liquid reflux	12749
@VP	avoid liquid reflux	12752
@VP	was sutured	12783
@VP	sutured	12787
@VP	allowed to recover in a warm environment	12811
@VP	to recover in a warm environment	12819
@VP	recover in a warm environment	12822
@VP	were expressed twice a day until reflex voiding of the bladder was reestablished	12862
@VP	expressed twice a day until reflex voiding of the bladder was reestablished	12867
@VP	was reestablished	12925
@VP	reestablished	12929
@VP	To prevent infection	12944
@VP	prevent infection	12947
@VP	was given in the drinking water for 1 week	12989
@VP	given in the drinking water for 1 week	12993
@VP	was tested before surgery , and at 3 , 7 , 14 , 21 , 28 , 35 and 42 dpo	13112
@VP	tested before surgery , and at 3 , 7 , 14 , 21 , 28 , 35 and 42 dpo	13116
@VP	placed individually in a circular enclosure and allowed to move freely for 5 min	13192
@VP	placed individually in a circular enclosure	13192
@VP	allowed to move freely for 5 min	13240
@VP	to move freely for 5 min	13248
@VP	move freely for 5 min	13251
@VP	evaluated locomotion during open-field walking	13288
@VP	scored the hindlimb performance	13340
@VP	described	13737
@VP	captured ventral images of the animal at 140 frames/s	13855
@VP	were recorded	13956
@VP	recorded	13961
@VP	increased from 0 cm/s until the animal was not able to run at the selected speed	14041
@VP	was not able to run at the selected speed	14080
@VP	to run at the selected speed	14093
@VP	run at the selected speed	14096
@VP	were recorded at 20 cm/s , only if the animals were able to run at this speed	14172
@VP	recorded at 20 cm/s , only if the animals were able to run at this speed	14177
@VP	were able to run at this speed	14218
@VP	to run at this speed	14228
@VP	run at this speed	14231
@VP	were analysed as described elsewhere -LRB- Redondo-Castro et al. , 2013 -RRB-	14261
@VP	analysed as described elsewhere -LRB- Redondo-Castro et al. , 2013 -RRB-	14266
@VP	described elsewhere -LRB- Redondo-Castro et al. , 2013 -RRB-	14278
@VP	ending times of the stance phase of each step	14343
@VP	analysing the videos using ImageJ software -LRB- NIH , Bethesda MA , USA -RRB-	14407
@VP	using ImageJ software -LRB- NIH , Bethesda MA , USA -RRB-	14428
@VP	was depicted -LRB- McEwen & Springer , 2006 -RRB-	14497
@VP	depicted -LRB- McEwen & Springer , 2006 -RRB-	14501
@VP	previously extracted	14753
@VP	To assess the coordination of locomotion	14775
@VP	assess the coordination of locomotion	14778
@VP	was calculated	14843
@VP	calculated	14847
@VP	is exactly placed one time	14938
@VP	placed one time	14949
@VP	is placed or raised at a given time	14992
@VP	placed or raised at a given time	14995
@VP	were performed before surgery and at 42 dpo in both hindpaws	15292
@VP	performed before surgery and at 42 dpo in both hindpaws	15297
@VP	were habituated in the testing chamber for 10 min	15363
@VP	habituated in the testing chamber for 10 min	15368
@VP	connected to a force sensor	15558
@VP	was applied in the medial part of the hindpaw	15586
@VP	applied in the medial part of the hindpaw	15590
@VP	increased	15656
@VP	was determined as the force at which the animal withdrew the paw	15685
@VP	determined as the force at which the animal withdrew the paw	15689
@VP	withdrew the paw	15733
@VP	using a Plantar algesimeter -LRB- Ugo Basile , Comerio , Italy -RRB-	15798
@VP	withdrew the limb was used to determine the hot pain threshold	15951
@VP	was used to determine the hot pain threshold	15969
@VP	used to determine the hot pain threshold	15973
@VP	to determine the hot pain threshold	15978
@VP	determine the hot pain threshold	15981
@VP	was set at 20 s to prevent tissue damage	16030
@VP	set at 20 s to prevent tissue damage	16034
@VP	to prevent tissue damage	16046
@VP	prevent tissue damage	16049
@VP	separated by 10-min resting periods for each hindpaw	16084
@VP	were performed in both sensory tests	16137
@VP	performed in both sensory tests	16142
@VP	was the mean of both hindpaws	16199
@VP	were anesthetized with pentobarbital -LRB- 30 mg/kg i.p. -RRB-	16306
@VP	placed prone onto a metal plate and skin temperature	16360
@VP	maintained above 32 °C	16413
@VP	was used	16480
@VP	used	16484
@VP	consisted of the evaluation of motorevoked potentials -LRB- MEPs -RRB-	16515
@VP	were elicited by transcranial electrical stimulation of the brain	16582
@VP	elicited by transcranial electrical stimulation of the brain	16587
@VP	were applied	16849
@VP	applied	16854
@VP	ıas et al. , 2004 ; Valero-Cabr e et al. , 2004	17021
@VP	e et al.	17051
@VP	delivered by needles inserted percutaneously at the sciatic notch	17221
@VP	inserted percutaneously at the sciatic notch	17242
@VP	was inserted on the belly of the muscle and the reference at the fourth toe	17417
@VP	inserted on the belly of the muscle and the reference at the fourth toe	17421
@VP	were recorded in the same sweep	17586
@VP	recorded in the same sweep	17591
@VP	were measured	17698
@VP	measured	17703
@VP	e et al.	17937
@VP	was 42 days after injury	18036
@VP	injected with gMSC or gOEC	18102
@VP	were deeply anesthetized -LRB- pentobarbital 60 mg/kg i.p. -RRB-	18216
@VP	perfused with 4 % paraformaldehyde in PBS	18290
@VP	harvested	18437
@VP	post-fixed in the same fixative solution for 4 h	18451
@VP	cryopreserved in 30 % sucrose	18504
@VP	distributed in 15 series of 24 sections -LRB- separated by 450 µm -RRB-	18690
@VP	separated by 450 µm	18731
@VP	separated by 360 µm	18901
@VP	were collected onto gelatincoated glass slides	18937
@VP	collected onto gelatincoated glass slides	18942
@VP	was re-hydrated for 5 min in water , then	19049
@VP	were washed in water followed by 1 % HCl in ethanol solution for 30 s.	19222
@VP	washed in water followed by 1 % HCl in ethanol solution for 30 s.	19227
@VP	followed by 1 % HCl in ethanol solution for 30 s.	19243
@VP	washed with water again	19310
@VP	stained with Eosin Y -LRB- Merck Millipore , Dramstadt , Germany -RRB- for 6 min	19338
@VP	were dehydrated and mounted with DPX -LRB- Sigma -RRB-	19421
@VP	dehydrated and mounted with DPX -LRB- Sigma -RRB-	19426
@VP	to localize	19638
@VP	localize	19641
@VP	engrafted cells	19650
@VP	to visualize astroglial reactivity and the glial scar formed around the lesion	19817
@VP	visualize astroglial reactivity and the glial scar formed around the lesion	19820
@VP	formed around the lesion	19871
@VP	supplemented with 0.3 % Triton and 5 % FBS	20238
@VP	diluted in PBS plus 0.3 % Triton and 2.5 % FBS	20351
@VP	to detect non-specific staining	20855
@VP	detect non-specific staining	20858
@VP	used in this work	20907
@VP	were specific	20925
@VP	was detected in any of the negative controls used	20956
@VP	detected in any of the negative controls used	20960
@VP	used	21001
@VP	attached to the microscope -LRB- Olympus BX51 -RRB-	21087
@VP	separated by 360 µm between pairs	21204
@VP	were taken at 40 9 with the same setting	21293
@VP	taken at 40 9 with the same setting	21298
@VP	was mounted using Photoshop software -LRB- Adobe Systems -RRB-	21356
@VP	mounted using Photoshop software -LRB- Adobe Systems -RRB-	21360
@VP	using Photoshop software -LRB- Adobe Systems -RRB-	21368
@VP	were analysed using ImageJ software	21431
@VP	analysed using ImageJ software	21436
@VP	using ImageJ software	21445
@VP	was measured after defining a threshold for background correction	21505
@VP	measured after defining a threshold for background correction	21509
@VP	defining a threshold for background correction	21524
@VP	separated by 450 µm between pairs	21659
@VP	were taken at 40 9 with the same setting	21741
@VP	taken at 40 9 with the same setting	21746
@VP	spared tissue , cavity and total spinal cord sections	21795
@VP	were delineated and measured using ImageJ software for each section	21848
@VP	delineated and measured using ImageJ software for each section	21853
@VP	using ImageJ software for each section	21877
@VP	spared tissue , cavity and total SCI segment	21942
@VP	To study the effects of the cell grafts on glial reaction	22079
@VP	study the effects of the cell grafts on glial reaction	22082
@VP	corresponding to the epicenter	22251
@VP	was made in both gray and white matter	22350
@VP	made in both gray and white matter	22354
@VP	represented as the fraction with respect to the total spinal cord section area	22411
@VP	were analysed by one-way ANOVA	22599
@VP	analysed by one-way ANOVA	22604
@VP	were analysed using two-way ANOVA	22652
@VP	analysed using two-way ANOVA	22657
@VP	using two-way ANOVA	22666
@VP	were performed by twoway ANOVA of repeated measures	22757
@VP	performed by twoway ANOVA of repeated measures	22762
@VP	was used	22869
@VP	used	22873
@VP	< 0.05 was considered as significant , and mean SEM were represented	22916
@VP	< 0.05 was considered as significant	22916
@VP	considered as significant	22927
@VP	mean SEM were represented	22958
@VP	were represented	22969
@VP	represented	22974
@VP	were evaluated as survival curves by log-rank test	23021
@VP	evaluated as survival curves by log-rank test	23026
@VP	results	23106
@VP	using the BBB score in acute	23179
@VP	to support body weight	23471
@VP	support body weight	23474
@VP	were able to run at increasing treadmill speeds	23767
@VP	to run at increasing treadmill speeds	23777
@VP	run at increasing treadmill speeds	23780
@VP	was analysed as survival curves -LRB- C and D -RRB-	23815
@VP	analysed as survival curves -LRB- C and D -RRB-	23819
@VP	represents the statistical significance of the log-rank test	23890
@VP	showed similar disturbances -LRB- E and F , left panels -RRB-	24070
@VP	left panels	24108
@VP	assessed using the RI	24150
@VP	using the RI	24159
@VP	-LRB- E and F -RRB- * P < 0.05 SCI groups vs. intact control rats	24245
@VP	* P < 0.05 SCI groups vs. intact control rats	24255
@VP	* P <	24255
@VP	results	24326
@VP	using the BBB score in acute	24399
@VP	to support body weight	24691
@VP	support body weight	24694
@VP	were able to run at increasing treadmill speeds	24987
@VP	to run at increasing treadmill speeds	24997
@VP	run at increasing treadmill speeds	25000
@VP	was analysed as survival curves -LRB- C and D -RRB-	25035
@VP	analysed as survival curves -LRB- C and D -RRB-	25039
@VP	represents the statistical significance of the log-rank test	25110
@VP	showed similar disturbances -LRB- E and F , left panels -RRB-	25290
@VP	left panels	25328
@VP	assessed using the RI	25370
@VP	using the RI	25379
@VP	-LRB- E and F -RRB- * P < 0.05 SCI groups vs. intact control rats	25465
@VP	* P < 0.05 SCI groups vs. intact control rats	25475
@VP	* P <	25475
@VP	assessed using an electronic Von Frey device -LRB- A and B -RRB-	25597
@VP	using an electronic Von Frey device -LRB- A and B -RRB-	25606
@VP	using the Plantar test -LRB- C and D -RRB-	25673
@VP	indicating hypersensitivity in front to noxious mechanical and thermal stimuli	25919
@VP	were observed between acute or delayed transplant groups	26014
@VP	observed between acute or delayed transplant groups	26019
@VP	left panel	26187
@VP	were observed in the amplitude of the M-wave	26252
@VP	observed in the amplitude of the M-wave	26257
@VP	increased	26313
@VP	indicates hyper-reflexia in the spinal segments below the damage	26361
@VP	had a latency of about 6 ms -LRB- C , with arrow -RRB-	26714
@VP	disappeared	26792
@VP	was recorded with a latency of about 20 ms -LRB- D and E , black arrow -RRB-	26834
@VP	recorded with a latency of about 20 ms -LRB- D and E , black arrow -RRB-	26838
@VP	presented this response from TA	26976
@VP	represented for the acute -LRB- F and H , respectively -RRB-	27052
@VP	delayed -LRB- G and I , respectively -RRB- treatments	27106
@VP	# P < 0.05 MSC group	27202
@VP	divided according to acute -LRB- A -RRB-	27446
@VP	delayed -LRB- B -RRB-	27481
@VP	spared tissue area with respect to the total area of the section	27588
@VP	left panel	27930
@VP	was performed in transversal spinal cord sections -LRB- A -RRB-	28329
@VP	performed in transversal spinal cord sections -LRB- A -RRB-	28333
@VP	inset	28476
@VP	was counted	28483
@VP	counted	28487
@VP	were done in sections from 4 mm rostral to 4 mm caudal to the lesion epicenter	28503
@VP	done in sections from 4 mm rostral to 4 mm caudal to the lesion epicenter	28508
@VP	divided according to acute -LRB- B -RRB-	28604
@VP	delayed -LRB- C -RRB-	28639
@VP	* P	28817
@VP	inset	28946
@VP	divided according to acute -LRB- B -RRB-	29398
@VP	delayed -LRB- C -RRB-	29433
@VP	represent the white mater and the right graphs the gray matter measurements	29509
@VP	reactivity after SCI and cell transplantation	29929
@VP	was measured in the white mater -LRB- A1 and A2 -RRB-	30181
@VP	measured in the white mater -LRB- A1 and A2 -RRB-	30185
@VP	divided according to acute -LRB- B -RRB-	30385
@VP	delayed -LRB- C -RRB-	30420
@VP	observed in both rostral and caudal sections after MSC or OEC transplantation	30660
@VP	were no significant changes at the epicenter in any experimental condition	30745
@VP	found surrounding the epicenter of the injury	31089
@VP	surrounding the epicenter of the injury	31095
@VP	near the rostral and caudal injection sites -LRB- Fig. 1A -RRB-	31140
@VP	observed at 2 weeks	31239
@VP	further at 3 weeks after grafting in all groups -LRB- Fig. 1B -- D -RRB-	31263
@VP	grafting in all groups -LRB- Fig. 1B -- D -RRB-	31288
@VP	< 0.0001 ; Fig. 1E	31429
@VP	< 0.0001	31483
@VP	was larger after acute than delayed gMSC grafting at 1 week after injection	31525
@VP	grafting at 1 week after injection	31566
@VP	= 24.44 , P < 0.0001 ; Fig. 1E	31744
@VP	< 0.0001	31755
@VP	was measured in acute than in delayed transplants -LRB- Fig. 1F -RRB-	31866
@VP	measured in acute than in delayed transplants -LRB- Fig. 1F -RRB-	31870
@VP	delayed -LRB- Fig. 1H -RRB-	32018
@VP	were found	32074
@VP	found	32079
@VP	was quantified for both types of cells	32121
@VP	quantified for both types of cells	32125
@VP	was relatively short in time and decreased markedly 2 weeks after the transplant	32224
@VP	was relatively short in time	32224
@VP	decreased markedly 2 weeks after the transplant	32257
@VP	affected more their survival than delayed injection	32355
@VP	was used to test the gross voluntary locomotion activity after SCI	32463
@VP	used to test the gross voluntary locomotion activity after SCI	32467
@VP	to test the gross voluntary locomotion activity after SCI	32472
@VP	test the gross voluntary locomotion activity after SCI	32475
@VP	followed by recovery during the next 2 weeks	32627
@VP	were only a few differences between groups	32856
@VP	had higher scores than vehicle at 14 days -LRB- VE -- 7 dpo vs.	33174
@VP	were found between the acute	33365
@VP	found between the acute	33370
@VP	injected groups during the plateau phase	33411
@VP	were able to run at maximal treadmill speed about 80 cm/s	33482
@VP	to run at maximal treadmill speed about 80 cm/s	33492
@VP	run at maximal treadmill speed about 80 cm/s	33495
@VP	supported their weight in stance	33573
@VP	were able to run at 5 cm/s treadmill speed	33614
@VP	to run at 5 cm/s treadmill speed	33624
@VP	run at 5 cm/s treadmill speed	33627
@VP	walking at higher speeds	33739
@VP	were detected between OEC and VE acute groups	33976
@VP	detected between OEC and VE acute groups	33981
@VP	performed slightly better than the other two groups	34140
@VP	performed at 20 cm/s treadmill speed -LRB- Redondo-Castro et al. , 2013 -RRB-	34261
@VP	increased the forelimb step and reduced the hindlimb step number	34352
@VP	increased the forelimb step	34352
@VP	reduced the hindlimb step number	34384
@VP	decreased in forelimbs , while the stance time increased in hindlimbs	34476
@VP	increased in hindlimbs	34522
@VP	left panel ; F3 ,42 = 12.22 , P < 0.0001 ; Fig. 2F , left panel	34831
@VP	< 0.0001 ; Fig. 2F	34860
@VP	left panel	34879
@VP	alternating step pattern	34922
@VP	used as a measure of global coordination	34948
@VP	< 0.0001	35071
@VP	< 0.0001	35116
@VP	normalized to the pre-operative values for each animal	35356
@VP	evoked in all the animals two consecutive muscle responses	35689
@VP	was significantly changed in the SCI rats	35877
@VP	changed in the SCI rats	35895
@VP	increased after injury -LRB- Fig. 4A -RRB-	35954
@VP	< 0.0001 ; Fig. 4B	36162
@VP	left panel ; F = 55.15 , P < 0.0001 ; Fig. 4B , right panel	36181
@VP	< 0.0001	36206
@VP	mean amplitude of ~ 0.22 , ~ 14 and ~ 8.1 mV ,	36667
@VP	was abolished during the follow-up	36791
@VP	abolished during the follow-up	36795
@VP	appeared after injury in TA and GM muscles -LRB- Fig. 4D and E -RRB-	36987
@VP	was higher in MSC than OEC and VE groups -LRB- MSC -- 0 dpo vs.	37122
@VP	were found between groups	37462
@VP	found between groups	37467
@VP	considered separately the acute and subacute transplant groups	37768
@VP	< 0.0001	38019
@VP	grafted	38157
@VP	was only significant in the caudal region	38191
@VP	< 0.0001	38517
@VP	were no differences between groups in the amount of spared tissue	38585
@VP	To compare acute and delayed treatment	38652
@VP	compare acute and delayed treatment	38655
@VP	was calculated -LRB- Fig. 5C -RRB-	38731
@VP	calculated -LRB- Fig. 5C -RRB-	38735
@VP	was counted -LRB- Fig. 6A -RRB-	39127
@VP	counted -LRB- Fig. 6A -RRB-	39131
@VP	< 0.0001	39637
@VP	survived around the distal injection segments	39670
@VP	were found in the epicenter of the injury in any experimental group	39736
@VP	found in the epicenter of the injury in any experimental group	39741
@VP	was higher in the epicenter than in the distal sections	40147
@VP	was observed in both rostral -LRB- MSC -- 7 dpo vs.	40596
@VP	observed in both rostral -LRB- MSC -- 7 dpo vs.	40600
@VP	were found between type of cells in any of the histological analyses	41099
@VP	found between type of cells in any of the histological analyses	41104
@VP	is a widely debatable issue	41202
@VP	have shown therapeutic effects	41265
@VP	shown therapeutic effects	41270
@VP	used to evaluate the outcomes	41742
@VP	to evaluate the outcomes	41747
@VP	evaluate the outcomes	41750
@VP	making it complicated to compare published works from different laboratories	41778
@VP	complicated to compare published works from different laboratories	41788
@VP	to compare published works from different laboratories	41800
@VP	compare published works from different laboratories	41803
@VP	to determine the best option for spinal cord contusion injuries	41999
@VP	determine the best option for spinal cord contusion injuries	42002
@VP	provided by grafted MSCs and OECs	42155
@VP	treated with OECs	42363
@VP	induced higher hyper-reflexia	42408
@VP	achieve higher speed treadmill running and recovery of MEPs	42488
@VP	running	42519
@VP	compromises practically all the parenchyma at the epicenter	42785
@VP	extends tissue damage along several spinal cord segments	42849
@VP	shown by the abolition of MEPs	42990
@VP	reflected in improved recovery of overground locomotion or gait coordination	43429
@VP	was observed in the acute MSC transplanted rats	43548
@VP	observed in the acute MSC transplanted rats	43552
@VP	provided by the acute MSC graft	43641
@VP	may be related to the recovery of responses in MEPs observed in these animals	43673
@VP	be related to the recovery of responses in MEPs observed in these animals	43677
@VP	related to the recovery of responses in MEPs observed in these animals	43680
@VP	observed in these animals	43725
@VP	was low in comparison to intact animals	43788
@VP	achieved by the acute MSC treated group	43847
@VP	treated group	43873
@VP	was similar to the other groups	43887
@VP	remained severely affected compromising the gross locomotion performance	44487
@VP	severely affected compromising the gross locomotion performance	44496
@VP	compromising the gross locomotion performance	44514
@VP	caudal to the lesion	44651
@VP	transplanted	44950
@VP	contribute to the recovery of locomotion after SCI -LRB- Pearson , 2001 -RRB-	45028
@VP	grafted rats together with the partial recovery of MEPs	45594
@VP	may explain the improvement of these animals on the treadmill testing	45650
@VP	explain the improvement of these animals on the treadmill testing	45654
@VP	were found in the algesimetry tests	45789
@VP	found in the algesimetry tests	45794
@VP	did not revert the increased hyperalgesia after injury	45851
@VP	revert the increased hyperalgesia after injury	45859
@VP	were no significant differences between acute and subacute cell transplants	46381
@VP	was similarly disrupted in all the SCI groups	46512
@VP	disrupted in all the SCI groups	46526
@VP	engrafted cells into the epicenter	46579
@VP	seemed insufficient to counteract the tissue damage	46614
@VP	to counteract the tissue damage	46634
@VP	counteract the tissue damage	46637
@VP	induced may contribute to these discrepancies	47063
@VP	may contribute to these discrepancies	47071
@VP	contribute to these discrepancies	47075
@VP	Accompanying tissue preservation	47110
@VP	survived after cell transplantation in areas surrounding the epicenter	47171
@VP	surrounding the epicenter	47216
@VP	provided by the engrafted cells	47263
@VP	engrafted cells	47279
@VP	improving the survival of neurons in the segments of the thoracic injury	47468
@VP	has low relevance for the locomotor performance	47550
@VP	controlled by the injured spinal cord segments	47675
@VP	caused by both MSC and OEC transplants	47804
@VP	was previously reported	47848
@VP	can reduce the amount of damaged tissue	48132
@VP	reduce the amount of damaged tissue	48136
@VP	partly rescues neurons in the spared tissue	48182
@VP	reduces the chronic microglial / macrophage presence	48230
@VP	indicated similar amounts of MSCs and OECs during the first week after injection	48322
@VP	measured the two following weeks	48444
@VP	described	48492
@VP	were described -LRB- Nauta & Fibbe , 2009 -RRB-	48831
@VP	described -LRB- Nauta & Fibbe , 2009 -RRB-	48836
@VP	has been previously reported	48974
@VP	been previously reported	48978
@VP	previously reported	48983
@VP	indicative of an immunogenic reaction against these cells	49402
@VP	to determine the reason for the poor grafted cell survival	49481
@VP	determine the reason for the poor grafted cell survival	49484
@VP	grafted cell survival	49518
@VP	to establish immunosuppressive co-treatments	49544
@VP	establish immunosuppressive co-treatments	49547
@VP	show no differences in time-survival between MSCs and OECs	49612
@VP	could be important for the treatment success	49726
@VP	be important for the treatment success	49732
@VP	does not explain the differences found between MSC and OEC transplants	49784
@VP	explain the differences found between MSC and OEC transplants	49793
@VP	found between MSC and OEC transplants	49817
@VP	to provide beneficial effects after spinal cord contusion	49968
@VP	provide beneficial effects after spinal cord contusion	49971
@VP	are not robust after OEC treatment in the contusion model	50290
@VP	delayed OEC transplantation after contusion injury	50378
@VP	is the most complex and severe type of lesion to the spinal cord	50806
@VP	seems detrimental for the graft survival	51041
@VP	mimics the neuropathology of most human SCIs -LRB- Bunge et al. , 1997 -RRB-	51166
@VP	found in the MSC	51328
@VP	grafted groups	51345
@VP	make them more feasible for cell therapy in spinal cord contusion than OECs	51361
@VP	is an important point to consider for cell therapy	51545
@VP	to consider for cell therapy	51567
@VP	consider for cell therapy	51570
@VP	prevent damage	51637
@VP	protect the tissue -LRB- L opez-Vales et al. , 2006 , 2007 -RRB-	51656
@VP	could reduce the efficacy of the transplant	51776
@VP	reduce the efficacy of the transplant	51782
@VP	may be complicated	51882
@VP	be complicated	51886
@VP	may depend on the different experimental conditions	52245
@VP	depend on the different experimental conditions	52249
@VP	injected	52429
@VP	are still necessary for determining the optimal cell therapy strategy for SCI	52471
@VP	determining the optimal cell therapy strategy for SCI	52495
